# EDGAR Filing Document

**Accession Number:** 0001672571
**File Stem:** 0001493152-25-026417
**Filing Date:** 2025-12
**Character Count:** 229197
**Document Hash:** a7ee887270ca628c9403b2647bccff96
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-026417.hdr.sgml**: 20251205

**ACCESSION NUMBER**: 0001493152-25-026417

**CONFORMED SUBMISSION TYPE**: POS AM

**PUBLIC DOCUMENT COUNT**: 32

**FILED AS OF DATE**: 20251205

**DATE AS OF CHANGE**: 20251205

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Antiaging Quantum Living Inc.
- **CENTRAL INDEX KEY:** 0001672571
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-DIRECT MAIL ADVERTISING SERVICES [7331]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 472643986
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** POS AM
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-211051
- **FILM NUMBER:** 251553633

**BUSINESS ADDRESS:**
- **STREET 1:** 135-22 NORTHERN BLVD
- **STREET 2:** 2ND FL
- **CITY:** FLUSHING
- **STATE:** NY
- **ZIP:** 11354
- **BUSINESS PHONE:** 9174705393

**MAIL ADDRESS:**
- **STREET 1:** 135-22 NORTHERN BLVD
- **STREET 2:** 2ND FL
- **CITY:** FLUSHING
- **STATE:** NY
- **ZIP:** 11354

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Achison Inc
- **DATE OF NAME CHANGE:** 20160419

**Registration No. 333-211051**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**post-effective amendment** **NO: 1**

**FORM S-1**

**REGISTRATION STATEMENT**

**UNDER THE SECURITIES ACT OF 1933**

**Antiaging Quantum Living Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **New York** | **1040** | **47-2643986** |
| (State or other jurisdiction of<br> incorporation or organization) | (Primary Standard Industrial<br> Classification Code Number) | (I.R.S. Employer<br> Identification No.) |

---

**135-27 38<sup>th</sup> Avenue, #388**

**Flushing, New York 11354**

**(929) 990-3255**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Copy to:

**Cassi Olson<br> Celine and Partners, P.L.L.C.<br> 1185 6<sup>th</sup> Ave., Suite 353<br> New York, NY 10036<br> Telephone: (212) 612-1400**

**(718) 463-2555 — Facsimile**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Approximate date of commencement of proposed sale to the public:

**From time to time after this registration statement is declared effective.**

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: ☒

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer: ☐ Accelerated filer: ☐ Non-accelerated filer: ☒ Smaller reporting company: ☒ <br> Emerging Growth Company: ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

**The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.**

PROSPECTUS (Subject to Completion)

Dated: December 5, 2025

**Antiaging Quantum Living Inc.**

**4,280,342** **shares of Common Stock**

This prospectus relates to the potential offer and resale of up to 4,280,342 shares of Class A Common Stock, $0.00001 par value per share, (the **"**Shares" or "Common Stock**"**) of Antiaging Quantum Living Inc., by the stockholders identified herein (each, a "Selling Stockholder," and collectively, the "Selling Stockholders"). The 4,280,342 Shares reflect the exact number of shares issued upon the automatic conversion of the amended promissory notes, based on the final outstanding principal amounts of such notes and the fixed conversion price of $0.30 per share, as set forth in the executed Assignment and Amendment of Promissory Note agreements.

The registration of the Shares under this prospectus does not necessarily mean that any of the Shares will be offered or sold by the Selling Stockholders. We cannot predict if, when, or in what amounts any Selling Stockholder may sell any of the Shares.

The Selling Stockholders, or their respective transferees, pledgees, donees or other successors-in-interest, may sell the Common Stock through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The Selling Stockholders may sell any, all or none of the securities offered by this prospectus, and we do not know when or in what amount the Selling Stockholders may sell their shares of Common Stock hereunder following the effective date of this registration statement. We provide more information about how a Selling Stockholders may sell its shares of Common Stock in the section titled "Plan of Distribution" on page 34.

There is currently a limited public trading market for our Common Stock.

Our Common Stock is listed on the Over The Counter Pink Market ("OTC") under the symbol "AAQL." The last reported sale price of our common stock on the OTC on December 3, 2025, was $0.5723 per share.

We are registering the shares of Common Stock on behalf of the Selling Stockholders, to be offered and sold by them from time to time. We will not receive any proceeds from the sale of the Common Stock by the Selling Stockholders in the offering described in this prospectus. We have agreed to bear all of the expenses incurred in connection with the registration of the Common Stock. The Selling Stockholders will pay or assume discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred for the sale of the Common Stock.

**Investing in our securities involves a high degree of risk. Before making any investment decision, you should carefully review and consider all the information in this prospectus and the documents incorporated by reference herein, including the risks and uncertainties described under "Risk Factors" beginning on page 5.**

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

**We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision.**

The date of this prospectus is December 5, 2025

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [PROSPECTUS SUMMARY](#vv_001) | 1 |
| [ABOUT THIS OFFERING](#vv_002) | 4 |
| [RISK FACTORS](#vv_003) | 5 |
| [CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS](#vv_004) | 16 |
| [USE OF PROCEEDS](#vv_005) | 16 |
| [DETERMINATION OF OFFERING PRICE](#vv_006) | 17 |
| [DIVIDEND POLICY](#vv_007) | 17 |
| [MARKET PRICE OF AND DIVIDENDS ON COMMON EQUITY AND RELATED STOCKHOLDER MATTERS](#vv_008) | 17 |
| [DESCRIPTION OF BUSINESS](#vv_009) | 18 |
| [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#vv_011) | 23 |
| [MANAGEMENT](#vv_010) | 27 |
| [EXECUTIVE COMPENSATION](#vv_012) | 28 |
| [SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT](#vv_013) | 30 |
| [CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS](#vv_014) | 31 |
| [DESCRIPTION OF CAPITAL STOCK](#vv_015) | 32 |
| [SELLING STOCKHOLDERS](#vv_016) | 33 |
| [PLAN OF DISTRIBUTION](#vv_017) | 34 |
| [DISCLOSURE OF SEC POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES](#vv_018) | 35 |
| LEGAL OPINION\* |  |
| [EXPERTS](#vv_020) | 35 |
| [INTERESTS OF NAMED EXPERTS AND COUNSEL](#vv_022) | 37 |
| [ADDITIONAL INFORMATION](#vv_021) | 37 |
| INDEX TO FINANCIAL STATEMENTS\* |  |

---

**You should rely only on the information contained in this prospectus. Neither we, nor the selling stockholders have authorized anyone to provide information different from that contained in this prospectus. We and the selling stockholders are offering to sell, and seeking offers to buy, Ordinary Shares only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our Shares.**

\* To be Filed by Amendment

i

**PROSPECTUS SUMMARY**

The following summary highlights selected information from this prospectus and may not contain all the information that is important to you. To understand our business and this offering fully, you should read this entire prospectus carefully, including the financial statements and the related notes beginning on page F-1. When we refer in this prospectus to the "Company," "our Company," "we," "us" and "our," we mean Antiaging Quantum Living Inc., a New York corporation, and its subsidiaries. This prospectus contains forward-looking statements and information relating to the Company.

**Our Company**

Antiaging Quantum Living Inc., previously known as Achison Inc., (the "Company") is a New York corporation formed on December 29, 2014. Our current principal executive office is located at 135-27 38th Avenue, #388, Flushing, New York 11354. Our telephone number is (929) 990-3255.

On July 1, 2019 Lansdale Inc., the principal stockholder of the Company ("Seller") which is controlled by the Company's prior President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the "Agreement") with Dazhong 368 Inc, (the "Buyer"), pursuant to which, among other things, Seller agreed to sell to the Buyer, and the Buyer agreed to purchase from Seller, a total of 9,000,000 shares of Class A common stock of the Company beneficially owned by Seller. The purchased shares represented approximately 90% of the Company's issued and outstanding shares of Class A common stock, resulting in a change of the control of the Company. On the same date, Mr. Wanjun Xie resigned from all positions in the Company and Mr. Dingshan Zhang was appointed as the President and Chief Executive Officer.

Prior to the change in management, the Company's business activities included holding and trading securities in the U.S. market, trading spot silver in Singapore, and trading whisky in the United Kingdom. Following the management transition, the Company shifted its strategic focus to online advertising operations through its website, www.dazhong368.com, primarily targeting the New York market.

The website, which was established by Mr. Zhang in 2014, provides advertising services for professional individuals and companies across industries such as real estate, professional services, accounting, and legal services. We generate revenue by charging fixed service fees for advertisements posted on the Website. While this U.S.-based advertising business has historically produced modest but stable revenue with relatively low direct costs, its overall contribution to our consolidated profit margins remains limited due to the small scale of the platform and the fixed nature of customer-fee arrangements. As part of our broader strategy to improve profitability, we continue to evaluate and pursue additional business opportunities, including the expansion of our PRC operations, which have demonstrated stronger revenue growth and higher-margin potential through technical-service fees, distributor-support services, and non-medical health management activities. We believe these operational initiatives may enhance our long-term margins compared to reliance on the U.S. advertising business alone.

On March 21, 2023, the Company entered into a stock purchase agreement with Barry Wan entered whereby Mr. Wan acquired 29,215,000 restricted shares of Common Stock of the Company, representing approximately 97.4% of the Company's total issued and outstanding Common Stock from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company's then President, Chief Executive Officer and sole director, Dingshan Zhang.

[**Table of Contents**](#V_0000001)

On April 10, 2023, upon closing of the transaction, Barry Wan transferred all his acquired shares to New Lite Ventures LLC, (also known as New Living Ventures LLC) a Delaware Limited Liability Company which Barry Wan is the sole member. The foregoing transaction resulted in a change of control of the Company, with New Lite Ventures LLC becoming the beneficial owner of 97.4% of the Company's issued and outstanding common stock. Both before and after the transactions, the Company had 29,995,000 shares of its Common Stock issued and outstanding.

In connection with the transaction, on April 10, 2023, Mr. Dingshan Zhang resigned from all positions he held with the Company and Ms. Jing Wan was appointed as the Chief Executive Officer, Chief Financial Officer, President and Director. On June 16, 2023, Mr. Barry Wan was appointed Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Chairman of the Board of Directors of the Company upon Ms. Jing Wan's resignation. The Company was renamed Antiaging Quantum Living Inc. on June 14, 2023. Along with the name change, the ticker symbol of the Company was changed to "AAQL". The Company plans to continue its existing operations through its website at <u>www.dazhong368.com</u>, which, since 2014, has provided online advertising to different individuals or companies operating in real estate, accounting, legal and other professional services in the New York City area. Its revenues are generated from advertising fees.

On December 29, 2023, the board of directors of the Company approved the expansion of its operations into the global market, specifically targeting the Asia-Pacific and Chinese markets. In line with this expansion, the Company established multiple subsidiaries follows: AAQL Inc. ("BVI Holding"), a British Virgin Islands Company wholly owned by the Company, AAQL HK Limited ("Hong Kong Holding"), a wholly-owned subsidiary of BVI Holding, Antiaging Doctor Hangzhou Holding LTD ("Dao Ling Doctor Hangzhou"), a wholly-owned subsidiary of Hong Kong Holding, Dao Ling Doctor (Zhejiang) Health Management Limited ("Dao Ling Doctor Zhejiang"), a wholly-owned subsidiary of Dao Ling Doctor Hangzhou, and Dao Ling Doctor (Huzhou) Health Management Limited ("Dao Ling Doctor Huzhou"), a wholly-owned subsidiary of Dao Ling Doctor Hangzhou. As a result of this transition, the Company is no longer considered a "shell company," as defined under 17 CFR § 240.12b-2, and is now actively engaged in business operations through its subsidiaries.

On September 6, 2024, the holders of a majority of the issued and outstanding voting securities of the Company approved an amendment to its Certificate of Incorporation increase in the number of authorized shares of Common Stock of the Company from thirty million (30,000,000) shares of Common Stock, par value $0.001 per share, to six billion (6,000,000,000) shares of Common Stock, par value $0.00001 per share (the "Authorized Capital Increase"). Upon the effectiveness of the Authorized Capital Increase, the shares of Common Stock will be categorized as follows: 1,200,000,000 Class A shares, 1,200,000,000 Class B shares, 1,200,000,000 Class C shares, 1,200,000,000 Class D shares, and 1,200,000,000 Class E shares. On the same day, the Certificate of Amendment to the Certificate of Incorporation of the Company was filed with New York State Department effectuating the Authorized Capital Increase.

Dao Ling Doctor Zhejiang is our primary operating subsidiary in the PRC and conducts substantially all revenue-generating activities associated with the "Dao Ling Doctor" brand. Its core business consists of providing technical development, system maintenance, and platform-support services to the brand's distributors, including software configuration, ongoing system updates, and operational support for distributor-facing tools. Dao Ling Doctor Zhejiang earns technical service fees for these services, which represent the majority of our PRC-based revenue.

Dao Ling Doctor (Huzhou) Health Management Co., Ltd. ("Dao Ling Doctor Huzhou") engages in early-stage, ancillary business activities that support the future development of the Dao Ling Doctor ecosystem. Its primary services include non-medical health-consulting services (excluding diagnosis or treatment), network and information-security software development, and big-data processing services. Its "other services" consist of ancillary operational support, including technical research, preliminary product-development work, and internal system-support functions that assist Zhejiang's revenue-generating operations. At present, Huzhou does not contribute a material portion of the Company's revenue.

Since the fourth quarter of 2024 and throughout fiscal 2025 and to date, our operating activities have continued to expand across both our online advertising business and our Dao Ling Doctor subsidiaries. As reflected in our Annual Report on Form 10-K for the fiscal year ended March 31, 2025 and our Quarterly Reports on Form 10-Q for the quarters ended June 30 and September 30, 2025, we have experienced increases in revenues generated by our PRC subsidiaries, including growth in technical service fees, distributor support services, and non-medical health management activities. Our PRC subsidiaries have also expanded their customer base and increased accounts receivable during these periods, reflecting an increased volume of service contracts and business activity. Meanwhile, our U.S. advertising business continues to generate revenue from professional service providers in the New York metropolitan area through our www.dazhong368.com platform. Our operations during this period also reflect increased general and administrative expenses associated with personnel, lease obligations, and the operation of our expanding technical service infrastructure in China.

[**Table of Contents**](#V_0000001)

We provide an "ID card introduction" service for each of our customers, offering a personalized profile page to showcase their business information. In addition, we assist customers in maintaining and updating the content posted on their profile pages. We believe this one-stop service approach enhances customer experience and improves our ability to attract and retain potential clients.

**Corporate Information**

Our executive offices are located at 135-27 38th Ave #388, Flushing, NY 11354 and our telephone number is (929) 990-3255. Our website address is <u>www.dazhong368.com.</u> Except for any documents that are incorporated by reference into this prospectus that may be accessed from our website, the information available on or through our website is not part of this prospectus.

**Promissory Notes and November 2025 Amendments**

On December 31, 2024, we issued an aggregate of $1,667,701 in promissory notes (the **"**Notes**"**) to five lenders in the following principal amounts: (i) $383,598 to Tairan Baohe Insurance Sales Co., Ltd. (**"**Tairan**"**); (ii) $29,571 to New Lite Ventures LLC, a Delaware limited liability company controlled by our Chief Executive Officer and director, Mr. Barry Wan; (iii) $428,789.50 to Mr. Barry Wan; (iv) $287,174 to Hemeihui E-Commerce Co., Ltd.; and (v) $538,568 to Hemeihui E-Commerce Co., Ltd. The proceeds of the Notes were used for general working capital purposes.

The Notes were unsecured, non-interest-bearing loan obligations and did not contain any conversion rights, equity features, or other provisions that would render them securities at the time of issuance. The Notes were payable on demand and were not issued as part of a securities offering.

As disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2025, the Tairan Note, in the principal amount of $383,598, was repaid in full as of March 31, 2025, and therefore was not amended, assigned, or converted.

On November 25, 2025, we entered into four separate assignment and amendment of promissory note agreements (each, an "Assignment and Amendment Agreement," and collectively, the "Assignment and Amendment Agreements") with the holders of the four outstanding Notes, excluding the repaid Tairan Note. Under each Assignment and Amendment Agreement, the applicable holder (each, an "Assignor") transferred and assigned all of its rights, title, and interest in its Note to Atlantic Equity Holdings Inc. or Empire Street Capital Inc. (each, an "Assignee," and collectively, the "Assignees"), with our consent. Following each assignment, the applicable Note was amended to provide that the outstanding principal amount would automatically convert into shares of our Class A Common Stock at a fixed conversion price of $0.30 per share.

Immediately upon the effectiveness of the amendments, the four outstanding Notes automatically converted into an aggregate of 4,280,340 shares of our Class A Common Stock (the **"**Conversion Shares**"**).

**Implications of Being an Emerging Growth Company**

As a company with less than $1.235 billion in revenue during our last fiscal year, we qualify as an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the "JOBS Act"). As long as we remain an emerging growth company, we may rely on exemptions from certain reporting requirements applicable to other public companies that are not emerging growth companies. These exemptions include: (1) being permitted to provide only two years of selected financial data and two years of audited financial statements, together with reduced "Management's Discussion and Analysis" disclosure; (2) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act regarding the effectiveness of internal control over financial reporting; and (3) being exempt from new or revised financial accounting standards until such standards apply to private companies. We have elected to "opt out" of the extended transition period for complying with new or revised accounting standards and will comply with such standards as they become applicable to public companies. This election is irrevocable.

We will remain an emerging growth company until the earliest of: (1) the last day of our fiscal year during which we have total annual gross revenues of at least $1.235 billion; (2) the last day of the fiscal year following the fifth anniversary of the completion of this offering; (3) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (4) the date on which we become a "large accelerated filer," which would occur if we have been a public company for at least 12 months and the market value of our Common Stock held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter.

[**Table of Contents**](#V_0000001)

**SUMMARY OF THE OFFERING**

---

| | |
|:---|:---|
| **Common Stock Offered by Selling Stockholders** | Up to 4,280,342 shares, representing the actual number of shares issued upon conversion of the amended promissory notes at the fixed $0.30 conversion price. |
| **Common Stock Issued and Outstanding Prior to the Offering** | 34,275,342 shares |
| **Common Stock Issued and Outstanding After the Offering** | 34275342 |
| **Use of Proceeds** | We will not receive any proceeds from the sale of shares of our Common Stock by the selling stockholders. |
| **Market for our Common Stock**<br>| There is no assurance that a trading market will develop, or, if developed, that it will be sustained. Consequently, a purchaser of our Common Stock may find it difficult to resell the securities offered herein should the purchaser desire to do so when eligible for public resale.<br>|
| **Over The Counter Market Symbol** | AAQL |
| **Risk Factors** | You should carefully read "Risk Factors" in this prospectus for a discussion of factors that you should consider before deciding to invest in our Common Stock. |

---

[**Table of Contents**](#V_0000001)

**RISK FACTORS**

*An investment in our Common Stock is highly speculative, involves a high degree of risk and should be made only by investors who can afford a complete loss. You should carefully consider the following risk factors, together with the other information in this prospectus, including our financial statements and the related notes, before you decide to buy our Common Stock. The risks described below are not the only risks facing the Company. Other risks that we do not currently anticipate, or that we currently deem immaterial, may also materially adversely affect our business, financial condition, results of operations, and prospects..* 

***We have a limited operating history under our current business model, and our recent expansion into the PRC technical-services and health-management markets makes it difficult to evaluate our prospects.***

We have only a limited operating history with our current business model. Although we historically operated an online advertising business in the New York metropolitan area, beginning in late 2023 we expanded our operations into the Asia-Pacific region through our Dao Ling Doctor subsidiaries, which provide technical development, platform maintenance, distributor support services, and non-medical health-management services. Because these PRC subsidiaries began generating revenue only recently and continue to scale their operations, we face many of the risks and uncertainties associated with a newly expanded business.

For the fiscal year ended March 31, 2025 and the quarter ended September 30, 2025, a significant portion of our revenues was generated by our PRC subsidiaries rather than our legacy U.S. advertising business. However, we have a short operating history in these markets and limited experience managing cross-border operations, increasing accounts receivable, evolving service-delivery models, and the regulatory and compliance obligations applicable to PRC-based technical and consulting service providers. Our limited history makes it difficult for investors to evaluate our ability to maintain and grow these operations, accurately forecast revenues, or achieve or sustain profitability.

If we fail to address the risks and uncertainties associated with our recently expanded business, our results of operations, financial condition, and prospects could be materially and adversely affected.

***Because the Company is an "emerging growth company," the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies."***

The Company is an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). We will remain an emerging growth company until the earliest of:

&nbsp;&nbsp;&nbsp;&nbsp;(i) the
 last day of the fiscal year in which our total annual gross revenues exceed $1.235 billion;

(ii) the
 date on which we become a "large accelerated filer," which would occur if the market value of our Common Stock held by
 non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter; or

(iii) the
 date on which we have issued more than $1.0 billion in non-convertible debt during the preceding three-year period.

As an "emerging growth company", the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies" including, but not limited to:

● not being required to comply with the auditor attestation requirements of section 404(b) of the *Sarbanes-Oxley Act* ("Sarbanes Oxley") (we also will not be subject to the auditor attestation requirements of section 404(b) as long as we are a "smaller reporting company", which includes issuers that had a public float of less than $75 million as of the last business day of their most recently completed second fiscal quarter);

● reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and

● exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

[**Table of Contents**](#V_0000001)

In addition, section 107 of the JOBS Act provides that an "emerging growth company" can take advantage of the extended transition period provided in section 7(a)(2)(B) of the Securities Act of 1933 (the "Securities Act") for complying with new or revised accounting standards. Under this provision, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, the Company choosing to "opt out" of such extended transition period and, as a result, the Company will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section 107 of the JOBS Act provides that the Company's decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.

***We may have difficulty raising additional capital, which could deprive us of necessary resources.***

We expect to continue devoting significant capital resources to fund our business expansion. In order to support the initiatives envisioned in our business plan, we will need to raise additional funds through the sale of our products, public or private debt or equity financing, collaborative relationships or other arrangements. Our ability to raise additional financing depends on many factors beyond our control, including the state of capital markets, the market price of our Common Stock and the prospects for the development of competitive products by others. Because our Common Stock is quoted on the Over the Counter Market, many institutions and retail investors may be unwilling or unable to invest, or may require steep discounts. Sufficient additional financing may not be available to us or may be available only on terms that would result in further dilution to the current owners of our Common Stock.

***Our management team lacks experience in managing a public company and complying with laws applicable to such a company, the failure of which may adversely affect our business, financial conditions and results of operations.***

Our current management team has limited experience in managing a publicly traded company, interacting with public company investors, and complying with the complex laws and regulations applicable to public companies. Although our Common Stock is quoted on the Over the Counter Market, our Company has only recently become subject to the full reporting and compliance obligations of the federal securities laws. Our management has limited experience operating a public company and may not successfully or efficiently manage our ongoing public company responsibilities. Compliance with these obligations—including the preparation of required SEC reports, maintenance of adequate internal controls, responding to SEC comments, and satisfying corporate governance requirements—will require significant time and attention from our senior management. These demands may divert management's attention from the day-to-day operations of our business, which could adversely affect our business, financial condition and results of operations.

***We are dependent upon our only key executive who is not bound by any employment agreement nor does the Company maintain director and officers ("D&O") liability insurance for him.***

Our business and prospects depend substantially on the continued leadership and involvement of our sole key executive officer, who currently serves as our Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Chairman of the Board. His knowledge of our markets, operations, strategic relationships and internal processes is critical to our business and cannot be easily replaced. We do not have an employment or non-competition agreement with him, and he may terminate his relationship with us at any time. In addition, the Company does not maintain directors and officers ("D&O") liability insurance covering him.

Our ability to execute our business strategy—both in the United States and through our Dao Ling Doctor subsidiaries in the PRC—also depends on our ability to attract, train, and retain additional qualified managerial, financial, operational, and technical personnel. We operate with a small management team, and our recent expansion has increased the demands on our executive leadership. Competition for skilled personnel is intense, and we may be unable to hire or retain individuals with the experience necessary to support our growth.

The loss of our key executive, or our inability to successfully attract and retain additional qualified personnel, could materially and adversely affect our business, financial condition, and results of operations.

[**Table of Contents**](#V_0000001)

***We may be forced to curtail or discontinue operations if we are unable to obtain, on commercially acceptable terms, additional capital that we may require from time to time in the future to finance our operations and growth.***

We will require additional capital from time to time to support our operations, fund working capital needs, and continue implementing our business strategy. Although our revenues have increased, we have incurred recurring net losses and maintained a significant accumulated deficit, and our operations have historically relied on related-party loans and short-term financing arrangements. As of September 30, 2025, we had a shareholders' deficit and substantial amounts due to related parties, and our liquidity remains limited. If our operations expand more quickly than expected, if our PRC subsidiaries require additional investment, or if we experience delays in collecting accounts receivable, we may need to raise additional capital sooner than anticipated.

We cannot assure you that additional financing will be available when needed, on terms acceptable to us, or at all. If we raise additional capital through the issuance of equity, convertible securities, or other equity-linked instruments, existing stockholders may experience dilution, and new securities could have rights, preferences, or privileges senior to those of our Common Stock. If adequate funds are not available, or are not available on acceptable terms, we may be unable to support our expansion, invest in product and service development, meet our obligations, or respond effectively to competitive pressures. Any such inability could materially and adversely affect our business, financial condition, and results of operations.

***We face intense competition and could lose market share to our competitors, which could adversely affect our business, operating results and financial condition.***

We operate in highly competitive industries, and we face significant competition from both established and emerging companies. Our U.S. online advertising platform competes with numerous providers of digital advertising services, including local competitors, online directories, and large, well-capitalized technology companies with substantially greater financial resources, broader customer bases, stronger brand recognition, and more advanced advertising technologies. Many of these competitors are able to devote significantly larger marketing, development, and operational budgets to their platforms, making it difficult for us to attract and retain customers.

In addition, our Dao Ling Doctor subsidiaries in the PRC operate in rapidly developing and highly competitive markets for technical development services, distributor support, and non-medical health-management services. These markets include large, established technology companies as well as smaller regional service providers that may offer similar services at lower prices or with greater functionality, scale, or reach. Technological innovation, platform capabilities, service quality, and customer acquisition efforts all play a significant role in competitive performance in these industries.

We also face indirect competition from companies outside our principal markets. Businesses that offer health, wellness, lifestyle, or professional-services platforms, whether digital or offline, may be viewed by customers as substitutes for our advertising, technical-service, or health-management offerings. Shifts in consumer preferences toward alternative advertising channels or competing health-management solutions could reduce demand for our services.

If we fail to compete effectively in any of these markets, we could lose customers, experience reduced pricing power, or fail to achieve or sustain meaningful market penetration. Any of these outcomes could materially and adversely affect our business, financial condition, and results of operations.

***Failure to protect our intellectual property could adversely affect our business.***

Our business relies on proprietary software, platform architecture, data, technical know-how, and trade secrets developed through our online advertising operations and our Dao Ling Doctor technical-services and health-management platforms. Because much of our intellectual property is unpatented, we rely primarily on trade-secret protections, internal controls, and contractual confidentiality obligations with employees, contractors, and service providers. These measures may not be adequate to prevent unauthorized use, misappropriation, or disclosure of our proprietary information.

[**Table of Contents**](#V_0000001)

Trade secrets are inherently difficult to protect, and we cannot assure you that our confidentiality agreements will be effectively enforced or will provide sufficient remedies in the event of a breach. If our proprietary source code, platform designs, customer data, or operational methodologies were disclosed or independently developed by competitors, our competitive position could be materially harmed.

We also rely on trademarks, domain names, and brand assets associated with our Company, our Dao Ling Doctor subsidiaries, and our online advertising platform. Failure to obtain, maintain, or enforce our trademark rights could prevent us from challenging third parties that adopt confusingly similar names or branding, which could lead to customer confusion or diminish the value of our brand.

Intellectual property disputes, whether brought by us or asserted against us, can be costly, time-consuming, and uncertain in outcome. An adverse determination could require us to change our branding, redesign our platforms, cease use of certain proprietary materials, or enter into costly licensing arrangements.

Any failure to protect, enforce, or maintain our intellectual property rights could materially and adversely affect our business, results of operations, and financial condition.

***We may not be able to develop, maintain or enhance our brand.***

Our ability to attract and retain customers depends in part on our ability to build, maintain, and enhance the brand recognition of both our online advertising platform and the service offerings provided by our Dao Ling Doctor subsidiaries in the PRC. Because we operate with limited financial resources and relatively low brand visibility compared to larger competitors, developing a strong and trusted brand requires significant investment in marketing, customer support, service quality, and platform performance. We may not be able to devote sufficient capital or personnel to these efforts, and our branding initiatives may not achieve the desired results.

Any negative publicity, whether accurate or not, regarding our Company, our management, our PRC subsidiaries, our data practices, our customer service, or the quality or availability of our offerings could damage our reputation and impair our ability to grow our user base. Negative publicity can also expose us to legal, regulatory, or commercial consequences, particularly given the sensitivity of the industries in which we operate.

If we are unable to successfully maintain or enhance our brand, effectively manage negative publicity, or allocate sufficient resources to branding and marketing, our ability to compete and grow our business could be materially and adversely affected.

 ***We will need to achieve commercial acceptance of our services to generate revenues and achieve profitability.***

Our ability to grow our business and achieve profitability depends on the continued and expanded commercial acceptance of our service offerings in both the United States and the PRC. We operate a small online advertising platform targeting the New York metropolitan area, and we recently expanded into technical development, distributor-support, and non-medical health-management services through our Dao Ling Doctor subsidiaries. These services have only recently begun generating meaningful revenue, and market demand for our offerings may develop more slowly than expected, change unexpectedly, or fail to develop at all.

Customers may choose competing platforms or alternative service providers, and new or superior services may emerge that reduce the attractiveness of our offerings. Shifts in customer preferences, technology changes, or industry developments may diminish or eliminate the need for our services. Because we operate with limited brand recognition and financial resources, we may be unable to invest sufficiently in marketing, service enhancements, customer support, or technology to drive sustained customer adoption.

We cannot predict the rate or extent to which commercial acceptance of our services will grow, if at all. If we are unable to cost-effectively attract customers, maintain service quality, or achieve broader market acceptance of our offerings, our revenue growth, business prospects, and ability to achieve profitability could be materially and adversely affected.

[**Table of Contents**](#V_0000001)

***We may not be successful in introducing new products and services or enhancing our existing products and services.***

We intend to continue developing new service offerings and improving our existing online advertising platform and the technical development, distributor-support, and non-medical health-management services provided by our Dao Ling Doctor subsidiaries. The development, launch, and enhancement of new or existing services involve significant risks and uncertainties, including technical challenges, integration issues, regulatory considerations in the PRC and the United States, delays in implementation, and the need for continued investment in personnel and infrastructure. Any of these factors could delay or prevent the successful introduction of new services.

There is no assurance that any new or enhanced services we introduce will meet customer needs, achieve the quality or functionality offered by competitors, or gain market traction. Customer preferences may shift, competitors may introduce superior alternatives, and we may lack the financial, technical, or operational resources necessary to keep pace with evolving market expectations.

If we fail to develop, enhance, or manage our services in a cost-effective and timely manner, or if our new or improved offerings do not achieve commercial acceptance, our ability to grow our business, and our financial condition and results of operations, could be materially and adversely affected.

***Consumer preferences for our services are difficult to predict and may change, and, if we are unable to respond quickly to new trends, our business may be adversely affected.***

Demand for our services, both our online advertising platform in the United States and the technical development, distributor-support, and non-medical health-management services offered by our Dao Ling Doctor subsidiaries in the PRC, is influenced by evolving consumer and business preferences, technology trends, economic conditions, and competitive offerings. Customer needs in these markets can shift quickly, and we may not be able to anticipate or respond effectively to such changes.

For example, demand for online advertising services may decline if businesses reduce marketing budgets due to economic pressures or shift spending to competing platforms with greater reach, technological sophistication, or brand recognition. Similarly, demand for our technical services and health-management offerings may be affected by changes in customer expectations, technological innovation, industry practices, or regulatory developments in the PRC.

Our ability to grow and maintain our customer base depends on accurately identifying emerging trends and adapting our offerings on a timely and cost-effective basis. If we fail to modify or enhance our services to meet changing customer needs, or if competitors introduce superior or more appealing alternatives, demand for our services could diminish.

A significant shift in consumer or business preferences away from our service offerings, or a failure to anticipate and adapt to evolving trends, could reduce our revenues, harm our brand perception, and materially and adversely affect our business, financial condition, and results of operations.

***Any failure by us to properly price our products and services could ‎have ‎a material adverse effect on our financial condition and results of operations.***

Because we have a limited operating history with our current service offerings, particularly the technical development, distributor-support, and non-medical health-management services provided by our Dao Ling Doctor subsidiaries, we lack significant historical data to accurately determine optimal pricing strategies. Our ability to attract new customers, retain existing customers, and scale our operations depends in part on setting prices that are competitive while also allowing us to recover operating costs, development expenditures, personnel expenses, and other overhead associated with delivering our services.

If our prices are set too high, potential customers may choose competing platforms or service providers. If our prices are set too low, we may be unable to generate adequate margins, cover our costs, or invest in improvements to our services. Competitive pressures, customer expectations, and market dynamics may also force us to adjust our pricing more quickly than anticipated, which could further compress margins.

[**Table of Contents**](#V_0000001)

Any failure to establish, implement, or maintain effective pricing strategies, whether in the United States or in the PRC, could reduce demand, erode our revenues, and have a material adverse effect on our financial condition and results of operations.

‎

***Our success depends on the continuing efforts of our senior management team and other key personnel and our business may be harmed if we lose their services.***

Our future success depends in part on the continued service, leadership, and strategic direction provided by our senior management team and other key personnel, including Barry Wan, our Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Chairman of the Board. Mr. Wan currently performs multiple critical functions within our organization, and the loss of his services for any reason could materially disrupt our operations. We may not be able to identify or recruit qualified replacements on a timely basis, or at all.

As our operations expand, both in the United States and through our Dao Ling Doctor subsidiaries in the PRC, we expect to hire additional managerial, technical, operational, and financial personnel. Competition for individuals with the skills necessary to support online advertising services, software development, platform maintenance, technical services, and health-management operations is intense. We are a relatively small company with limited financial and brand resources, which may make it difficult to attract and retain qualified candidates.

If we are unable to retain our senior management or key personnel, or if we fail to hire the additional skilled personnel needed to support our growth, our operations may be disrupted, our ability to execute our business strategy may be impaired, and our business, financial condition, and results of operations could be materially and adversely affected.

***If we are unable to build and scale an effective sales and service delivery infrastructure to meet demand for our services, our ability to execute our business plan will be impaired.***

We currently rely on a small direct sales and business-development team, as well as online customer acquisition through our website and the service channels used by our Dao Ling Doctor subsidiaries in the PRC. While our existing resources are sufficient to support our current level of operations, they may not be adequate as demand for our services grows or as our service offerings expand.

As we continue to develop our online advertising business in the United States and our technical development, distributor-support, and non-medical health-management service lines in the PRC, we will need to scale our sales, customer-support, and service-delivery capabilities. This may include hiring additional personnel, expanding into new geographic markets, strengthening our online sales channels, and investing in operational infrastructure. We may be unable to implement these initiatives in a timely or cost-effective manner, or at all.

If we fail to expand our sales and service capabilities, or if our efforts to do so are ineffective, we may be unable to meet customer demand, support our growth strategy, or achieve the operational scale required under our business plan. This could materially and adversely affect our business, financial condition, and results of operations].

***We may encounter disputes from time to time relating to the use of third-party intellectual properties.***

We rely on proprietary software, platform architecture, data, branding, and other intellectual property in connection with our online advertising services in the United States and the technical development, distributor-support, and non-medical health-management services provided by our Dao Ling Doctor subsidiaries in the PRC. We also utilize third-party software, technologies, data sources, and service tools in the normal course of our operations. We cannot assure you that our services, technologies, or any intellectual property we develop or use do not or will not infringe the rights of third parties.

As of the date of this prospectus, we are not aware of any ongoing legal proceedings or disputes alleging infringement of third-party intellectual property. However, disputes may arise from time to time regarding the scope of our rights, the validity of third-party rights, or the ownership or authorized use of certain technologies or content. Intellectual property infringement claims, whether with or without merit, could result in costly and time-consuming litigation, diversion of management attention, operational disruptions, or requirements that we cease using certain technology or enter into unfavorable licensing arrangements.

[**Table of Contents**](#V_0000001)

Any such dispute or claim could materially and adversely affect our business, financial condition, and results of operations.

***We may fail to adequately protect our intellectual property rights, and we may be exposed to intellectual property infringement claims by third parties.***

Our intellectual property, including our software, platform architecture, data, proprietary methodologies, trademarks, and other intangible assets, is important to our competitive position in both our online advertising business in the United States and our technical development and health-management service operations in the PRC. Although we may apply for additional trademark or other intellectual property protections in the future, we primarily rely on a combination of trademark laws, copyright laws, trade-secret protections, and confidentiality agreements with employees, contractors, and service providers to safeguard our rights.

Despite these measures, we cannot assure you that our intellectual property protections will be adequate. Unauthorized use, misappropriation, or independent development of our proprietary technology or branding by third parties may occur, and detecting or preventing such conduct may be difficult or impossible. We may need to initiate litigation or other legal proceedings to enforce our rights, which could be costly, time-consuming, uncertain in outcome, and disruptive to our operations.

At the same time, we may be subject to claims that our services, technologies, or branding infringe the intellectual property rights of others. Any such disputes, whether involving enforcement of our rights or defending against third-party claims, could divert management attention, require us to cease using certain intellectual property, force us to enter into costly licensing arrangements, or result in monetary damages.

Failure to adequately protect our intellectual property, or exposure to intellectual property disputes or infringement claims, could materially and adversely affect our business, financial condition, and results of operations.

 ***Adverse litigation judgments or settlements resulting from legal or arbitral proceedings in which we may be involved could expose us to monetary damages, equitable restraints or limit our ability to operate our business.***

We may from time to time become involved in litigation, arbitration, regulatory inquiries, or other legal proceedings in the ordinary course of our business. These matters may include commercial disputes, intellectual property claims, contract disagreements, employment matters, regulatory compliance issues, or other claims arising out of our online advertising services in the United States or our technical development and health-management operations in the PRC. Any such proceedings may be costly, time-consuming, and disruptive to our operations.

If a legal proceeding is resolved against us, we could be required to pay substantial monetary damages, comply with injunctive or other equitable relief, alter or discontinue certain business practices, or accept other remedies that could materially and adversely affect our ability to operate our business. Even if we ultimately prevail, litigation and arbitration require significant management attention and financial resources, may delay operational initiatives, and could create negative publicity or damage our reputation and brand.

We could also become involved in future disputes related to our service relationships, contractual arrangements, or other commercial matters. Any such legal or arbitral proceedings could materially and adversely affect our business, financial condition, results of operations, customer relationships, and ability to attract new clients.

***Our business may be materially adversely affected by new outbreaks, or continuation of any existing outbreaks, of any infectious disease (such as COVID-19) and other events.***

Our business, financial condition, and results of operations could be materially and adversely affected by new outbreaks, or the continuation or recurrence, of infectious diseases (such as COVID-19), as well as by other disruptive events such as natural disasters, extreme weather, political instability, armed conflicts, or acts of terrorism. Such events can negatively impact global and regional economic conditions, financial markets, consumer confidence, supply chains, and commercial activity.

[**Table of Contents**](#V_0000001)

We could also experience direct operational disruptions. For example, our employees or contractors, whether in the United States or in our PRC subsidiaries, may be required or advised to self-isolate or may otherwise be unable to work, reducing our operational capacity. Similarly, our customers could experience business slowdowns, temporary closures, staffing shortages, or financial stress, which could reduce demand for our services, delay projects, or lead to slower collections of accounts receivable.

The extent and duration of any impact from future outbreaks or disruptive events are inherently uncertain and depend on factors outside our control, including government responses, public-health measures, economic conditions, and the speed of recovery in affected regions. If such events persist or intensify, our business, results of operations, financial condition, cash flows, and the trading price of our Common Stock could be materially and adversely affected.

***We have limited insurance coverage with respect to our business and operations.***

We are exposed to various risks associated with our business and operations, and we have limited insurance coverage. See "Business—Insurance" for more information. We are exposed to risks including, among other things, accidents or injuries in our facilities, loss of key management and personnel, business interruption, natural disasters, terrorist attacks and social instability or any other events beyond our control. We do not have any business interruption insurance, product liability insurance or key-man life insurance. Any business disruption, legal proceeding or natural disaster or other events beyond our control could result in substantial costs and diversion of our resources, which may materially and adversely affect our business, financial condition and results of operations.

***Our employees may engage in misconduct or other improper activities.***

Like all companies, we face the risk of employee misconduct or other improper activities. Employee misconduct could include intentional failures to comply with laws and regulations, unauthorized activities, attempts to obtain reimbursement for improper expenses, or submission of falsified time records. Negative press reports regarding employee misconduct could harm our reputation, and if our reputation is negatively affected, our future revenues and growth prospects would be adversely affected. It is not always possible to deter employee misconduct, and the precautions we take to prevent and detect this activity may not be effective in controlling unknown or unmanaged risks or losses, which could harm our business, financial condition, results of operations and our ability to meet our financial obligations.

***Our inability to renew existing leases on favorable terms may adversely affect our results of operations.***

We operate our main business site located on leased premises. There can be no assurance we will be able to renew our expiring leases after the expiration of all remaining renewal options. As a result, our additional costs may incur to operate our business, including increased rent and other costs related to the negotiation of terms of occupancy of an existing leased premise. If we are unable to renew a lease or determine not to renew a lease, there may be costs related to the relocation and development of a replacement premise or, if we are unable to relocate, reduced revenue.

**Risks Relating to Our Common Stock**

***We have not paid dividends and do not expect to do so in the foreseeable future.***

We have not paid any dividends since our incorporation and do not anticipate the payment of dividends in the foreseeable future. At present, our policy is to retain earnings, if any, to develop and market our products. The payment of dividends in the future will depend upon, among other factors, our earnings, capital requirements, and operating financial conditions.

***Our Common Stock is subject to the "penny stock" rules of the SEC and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.***

Our Common Stock is subject to the "penny stock" rules of the SEC and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.

[**Table of Contents**](#V_0000001)

Under U.S. federal securities legislation, our Common Stock currently constitutes a "penny stock". Penny stock is any equity security that has a market price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require that a broker or dealer approve a potential investor's account for transactions in penny stocks, and the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. In order to approve an investor's account for transactions in penny stocks, the broker or dealer must obtain financial information and investment experience objectives of the person and make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks. The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prepared by the Securities and Exchange Commission (the "SEC") relating to the penny stock market, which, in highlight form sets forth the basis on which the broker or dealer made the suitability determination. Brokers may be less willing to execute transactions in securities subject to the "penny stock" rules. This may make it more difficult for investors to dispose of our Common Stock and cause a decline in the market value of our stock. Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

***We depend on our information technology systems, and any failure of these systems could harm our business.***

We depend on information technology and telecommunications systems for significant elements of our operations. Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts and natural disasters.

Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of our information technology or telecommunications systems or those used by our third-party service providers could prevent us from providing support services and product to our customers and managing the administrative aspects of our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could harm our business.

***Trading on the Over the Counter Market is volatile and sporadic, which could depress the market price of our Common Stock and make it difficult for the holders to resell their Common Stock.***

The Common Stock of the Company is quoted on the Over the Counter. Trading in securities quoted on the Over the Counter is often thin and characterized by wide fluctuations in trading prices, due to many factors, some of which may have little to do with our operations or business prospects. This volatility could depress the market price of the Common Stock for reasons unrelated to operating performance. Moreover, the Over the Counter is not a stock exchange, and trading of securities on the Over the Counter is often more sporadic than the trading of securities listed on Nasdaq. These factors may result in shareholders having difficulty reselling any Common Stock.

***The sales practice requirements of FINRA may limit a stockholder's ability to buy and sell our Common Stock.***

FINRA has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer's financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our Common Stock, which may limit the ability of our stockholders to buy and sell our Common Stock and could have an adverse effect on the market for and price of our Common Stock.

[**Table of Contents**](#V_0000001)

***The resale of shares covered by the Registration Statement could adversely affect the market price of our*** Common Stock ***in the public market, should one develop, which result would in turn negatively affect our ability to raise additional equity capital.***

The sale, or availability for sale, of our Common Stock in the public market may adversely affect the prevailing market price of our Common Stock and may impair our ability to raise additional capital by selling equity or equity-linked securities. The resale of a substantial number of shares of our Common Stock in the public market could adversely affect the market price for our Common Stock and make it more difficult for you to sell shares of our Common Stock at times and prices that you feel are appropriate. Furthermore, we expect that, because there will be a large number of shares registered pursuant to the Registration Statement, selling stockholders will continue to offer shares covered by such Registration Statement for a significant period of time, the precise duration of which cannot be predicted. Accordingly, the adverse market and price pressures resulting from an offering pursuant to the Registration Statement may continue for an extended period of time and continued negative pressure on the market price of our Common Stock could have a material adverse effect on our ability to raise additional equity capital.

***Issuance of stock to fund our operations may dilute your investment and reduce your equity interest.***

We may need to raise capital in the future to fund the development of our seafood business. Any equity financing may have significant dilutive effect to stockholders and a material decrease in our stockholders' equity interest in us. Equity financing, if obtained, could result in substantial dilution to our existing stockholders. At its sole discretion, our board of directors may issue additional securities without seeking stockholder approval, and we do not know when we will need additional capital or, if we do, whether it will be available to us.

**Risks Related to Our Shares and This Offering**

***If we are successful at creating a market for our Common Stock, the trading price of our Common Stock is likely to be volatile, which could result in substantial losses to investors.***

The trading price of our Common Stock is likely to be volatile and could fluctuate widely due to factors beyond our control. This may happen because of broad market and industry factors, including the performance and fluctuation of the market prices of other companies with business operations that have listed their securities in the United States. In addition to market and industry factors, the price and trading volume for our Common Stock may be highly volatile for factors specific to our own operations, including the following:

● variations in our revenues, earnings and cash flow;

● announcements of new investments, acquisitions, strategic partnerships or joint ventures by us or our competitors;

● announcements of new offerings, solutions and expansions by us or our competitors;

● changes in financial estimates by securities analysts;

● detrimental adverse publicity about us, our services or our industry;

● additions or departures of key personnel; and

● potential litigation or regulatory investigations.

Any of these factors may result in large and sudden changes in the volume and price at which our Common Stock will trade.

[**Table of Contents**](#V_0000001)

In the past, shareholders of public companies have often brought securities class action suits against those companies following periods of instability in the market price of their securities. If we were involved in a class action suit, it could divert a significant amount of our management's attention and other resources from our business and operations and require us to incur significant expenses to defend the suit, which could harm our results of operations. Any such class action suit, whether or not successful, could harm our reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial condition and results of operations.

***If securities or industry analysts do not publish research or reports about our business, or if they adversely change their recommendations regarding our Common Stock, the market price for our Common Stock and trading volume could decline.***

The trading market for our Common Stock will be influenced by research or reports that industry or securities analysts publish about our business. If one or more analysts who cover us downgrade our Common Stock, the market price for our Common Stock s would likely decline. If one or more of these analysts cease to cover us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the market price or trading volume for our Common Stock to decline.

***Negative publicity may harm our brand and reputation and have a material adverse effect on business.***

Negative publicity about us, including our services, management, business model and practices, compliance with applicable rules, regulations and policies, or our network partners may materially and adversely harm our brand and reputation and have a material adverse effect on our business. We cannot assure you that we will be able to defuse any such negative publicity within a reasonable period of time, or at all. Additionally, allegations, directly or indirectly against us, may be posted on the internet by anyone on a named or anonymous basis, and can be quickly and widely disseminated. Information posted may be inaccurate, misleading and adverse to us, and it may harm our reputation, business or prospects. The harm may be immediate without affording us an opportunity for redress or correction. Our reputation may be negatively affected as a result of the public dissemination of negative and potentially inaccurate or misleading information about our business and operations, which in turn may materially adversely affect our relationships with our customers, employees or business partners, and adversely affect the price of our Common Stock.

***Our operating results for a particular period may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause the price of our Common Stock to fluctuate or decline.***

We expect our operating results to be subject to fluctuations. Our operating results will be affected by numerous factors, including:

***●*** variations in the level of expenses related to future development plans;

***●*** fluctuations in value of the underlying commodity;

***●*** inability to procure sufficient quantities to meet demand due to the scarcity of the product available from its suppliers;

***●*** level of underlying demand for our products and any other products we sell;

***●*** any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved;

***●*** regulatory developments affecting us or our competitors; and

[**Table of Contents**](#V_0000001)

If our operating results for a particular period fall below the expectations of investors or securities analysts, the price of our Common Stock could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our Common Stock to fluctuate substantially. We believe that comparisons of our financial results from various reporting periods are not necessarily meaningful and should not be relied upon as an indication of our future performance.

***Issuance of stock to fund our operations may dilute your investment and reduce your equity interest.***

We may need to raise additional capital in the future to fund our operations, support working capital needs, expand our service offerings, and continue the development of our online advertising platform and our technical development and health-management service operations in the PRC. Any such capital raise may involve the issuance of equity securities, convertible securities, or other equity-linked instruments.

Issuing additional shares will dilute the ownership interests of existing stockholders and may adversely affect the market price of our Common Stock. Securities issued in future financings may have rights, preferences, or privileges senior to those of our current Common Stock, including with respect to dividends, liquidation preferences, voting rights, or other terms.

Our board of directors has the authority, without seeking stockholder approval unless required by applicable law or regulations, to issue additional securities at such times and on such terms as it determines to be appropriate. We cannot predict when we will require additional capital, the size or terms of any future offering, or whether such capital will be available on acceptable terms, or at all.

Any future equity financing could result in substantial dilution to our existing stockholders and may materially reduce their equity interest in our Company.

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, included in this prospectus regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Therefore, you should not place undue reliance on our forward-looking statements. We have included important risks and uncertainties in the cautionary statements included in this prospectus, particularly the section titled "Risk Factors" incorporated by reference herein. We believe these risks and uncertainties could cause actual results or events to differ materially from the forward-looking statements that we make. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections or expectations prove incorrect, actual results, performance or financial condition may vary materially and adversely from those anticipated, estimated or expected. Our forward-looking statements do not reflect the potential impact of future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any of the forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law. In the light of these risks and uncertainties, the forward-looking events and circumstances discussed in this prospectus may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.

**USE OF PROCEEDS**

We will not receive any proceeds from the sales of shares of our Common Stock by the Selling Stockholders.

[**Table of Contents**](#V_0000001)

**DETERMINATION OF OFFERING PRICE**

The Selling Stockholders may only sell their shares of our Common Stock pursuant to this prospectus at a fixed price of $0.30 per share until such time as our Common Stock is quoted on the OTCQB or another public trading market for our Common Stock otherwise develops. In order to be quoted on the OTCQB, a market maker must file an application on our behalf in order to make a market for our Common Stock. At and after such time, the selling stockholders may sell all or a portion of their shares through public or private transactions at prevailing market prices or at privately negotiated prices.

In determining the initial offering price of $0.30 per share (as stated above), we considered our Company's future prospects and those of our industry in general, our revenue, earnings and certain other financial and operating information in recent periods and the price-earnings ratios, price-sales ratios, market prices of securities and certain financial and operating information of companies engaged in activities similar to ours. We cannot assure you that the prices at which the Shares will sell in the public market after our Common Stock is listed or trading on an exchange or automated quotation system or quoted on the OTCQB Market (if ever) will not be lower than the initial offering price or that an active trading market in our Common Stock will develop or continue if developed.

**DIVIDEND POLICY**

We have never paid any cash dividends on our capital stock and do not anticipate paying any cash dividends on our Common Stock in the foreseeable future. We intend to retain future earnings to fund ongoing operations and future capital requirements. Any future determination to pay cash dividends will be at the discretion of our board of directors and will be dependent upon financial condition, results of operations, capital requirements and such other factors as the board of directors deems relevant.

**MARKET PRICE OF AND DIVIDENDS ON COMMON EQUITY**

**AND RELATED STOCKHOLDER MATTERS**

**Market Information**

Our Common Stock is quoted on the Over The Counter Pink Market ("OTC") under the symbol "AAQL." On December 5, 2025, the closing price on the OTC of our Common Stock was $0.5723

**Holders**

As of December 5, 2025, there were 36 holders of record of our Common Stock.

**Dividends**

We have never paid any cash dividends on our capital stock and do not anticipate paying any cash dividends on our Common Stock in the foreseeable future. We intend to retain future earnings to fund ongoing operations and future capital requirements. Any future determination to pay cash dividends will be at the discretion of our board of directors and will be dependent upon financial condition, results of operations, capital requirements and such other factors as the board of directors deems relevant.

**Securities Authorized for Issuance Under Equity Compensation Plans**

We have not adopted an Equity Compensation Plan.

**Sale of Restricted Shares**

All of the shares of our Common Stock outstanding are "restricted securities" as such term is defined in Rule 144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemption provided by Rule 144.

[**Table of Contents**](#V_0000001)

**DESCRIPTION OF BUSINESS**

**Company Overview**

Antiaging Quantum Living Inc., previously known as Achison Inc., (the "Company") is a New York corporation formed on December 29, 2014. Our current principal executive office is located at 135-27 38th Avenue, #388, Flushing, New York 11354. Our telephone number is (929) 990-3255.

On July 1, 2019 Lansdale Inc., the principal stockholder of the Company ("Seller") which is controlled by the Company's prior President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the "Agreement") with Dazhong 368 Inc, (the "Buyer"), pursuant to which, among other things, Seller agreed to sell to the Buyer, and the Buyer agreed to purchase from Seller, a total of 9,000,000 shares of Class A Common Stock of the Company beneficially owned by Seller. The purchased shares represented approximately 90% of the Company's issued and outstanding shares of Class A Common Stock, resulting in a change of the control of the Company. On the same date, Mr. Wanjun Xie resigned from all positions in the Company and Mr. Dingshan Zhang was appointed as the President and Chief Executive Officer.

Prior to the change in management, the Company's business activities included holding and trading securities in the U.S. market, trading spot silver in Singapore, and trading whisky in the United Kingdom. Following the management transition, the Company shifted its strategic focus to online advertising operations through its website, <u>www.dazhong368.com</u>, primarily targeting the New York market.

The website, which was established by Mr. Zhang in 2014, provides advertising services for professional individuals and companies across industries such as real estate, professional services, accounting, and legal services. We generate revenue by charging fixed service fees for advertisements posted on the Website. While this U.S.-based advertising business has historically produced modest but stable revenue with relatively low direct costs, its overall contribution to our consolidated profit margins remains limited due to the small scale of the platform and the fixed nature of customer-fee arrangements. As part of our broader strategy to improve profitability, we continue to evaluate and pursue additional business opportunities, including the expansion of our PRC operations, which have demonstrated stronger revenue growth and higher-margin potential through technical-service fees, distributor-support services, and non-medical health management activities. We believe these operational initiatives may enhance our long-term margins compared to reliance on the U.S. advertising business alone.

On March 21, 2023, the Company entered into a stock purchase agreement with Barry Wan entered whereby Mr. Wan acquired 29,215,000 restricted shares of Common Stock of the Company, representing approximately 97.4% of the Company's total issued and outstanding Common Stock from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company's then President, Chief Executive Officer and sole director, Dingshan Zhang.

On April 10, 2023, upon closing of the transaction, Barry Wan transferred all his acquired shares to New Lite Ventures LLC, (also known as New Living Ventures LLC) a Delaware Limited Liability Company which Barry Wan is the sole member. The foregoing transaction resulted in a change of control of the Company, with New Lite Ventures LLC becoming the beneficial owner of 97.4% of the Company's issued and outstanding Common Stock. Both before and after the transactions, the Company had 29,995,000 shares of its Common Stock issued and outstanding.

In connection with the transaction, on April 10, 2023, Mr. Dingshan Zhang resigned from all positions he held with the Company and Ms. Jing Wan was appointed as the Chief Executive Officer, Chief Financial Officer, President and Director. On June 16, 2023, Mr. Barry Wan was appointed Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Chairman of the Board of Directors of the Company upon Ms. Jing Wan's resignation. The Company was renamed Antiaging Quantum Living Inc. on June 14, 2023. Along with the name change, the ticker symbol of the Company was changed to "AAQL". The Company plans to continue its existing operations through its website at <u>www.dazhong368.com</u>, which, since 2014, has provided online advertising to different individuals or companies operating in real estate, accounting, legal and other professional services in the New York City area. Its revenues are generated from advertising fees.

[**Table of Contents**](#V_0000001)

On December 29, 2023, the board of directors of the Company approved the expansion of its operations into the global market, specifically targeting the Asia-Pacific and Chinese markets. In line with this expansion, the Company established multiple subsidiaries follows: AAQL Inc. ("BVI Holding"), a British Virgin Islands Company wholly owned by the Company, AAQL HK Limited ("Hong Kong Holding"), a wholly-owned subsidiary of BVI Holding, Antiaging Doctor Hangzhou Holding LTD ("Dao Ling Doctor Hangzhou"), a wholly-owned subsidiary of Hong Kong Holding, Dao Ling Doctor (Zhejiang) Health Management Limited ("Dao Ling Doctor Zhejiang"), a wholly-owned subsidiary of Dao Ling Doctor Hangzhou, and Dao Ling Doctor (Huzhou) Health Management Limited ("Dao Ling Doctor Huzhou"), a wholly-owned subsidiary of Dao Ling Doctor Hangzhou. As a result of this transition, the Company is no longer considered a "shell company," as defined under 17 CFR § 240.12b-2, and is now actively engaged in business operations through its subsidiaries.

On September 6, 2024, the holders of a majority of the issued and outstanding voting securities of the Company approved an amendment to its Certificate of Incorporation increase in the number of authorized shares of Common Stock of the Company from thirty million (30,000,000) shares of Common Stock, par value $0.001 per share, to six billion (6,000,000,000) shares of Common Stock, par value $0.00001 per share (the "Authorized Capital Increase"). Upon the effectiveness of the Authorized Capital Increase, the shares of Common Stock will be categorized as follows: 1,200,000,000 Class A shares, 1,200,000,000 Class B shares, 1,200,000,000 Class C shares, 1,200,000,000 Class D shares, and 1,200,000,000 Class E shares. On the same day, the Certificate of Amendment to the Certificate of Incorporation of the Company was filed with New York State Department effectuating the Authorized Capital Increase.

Since the fourth quarter of 2024 and throughout fiscal 2025 and to date, we have continued to expand our operations through both our U.S.-based online advertising platform and our PRC subsidiaries that operate under the "Dao Ling Doctor" brand. As disclosed in our Annual Report on Form 10-K for the year ended March 31, 2025 and our Quarterly Reports on Form 10-Q for the quarters ended June 30 and September 30, 2025, our PRC subsidiaries generated increasing revenues from technical service fees, distributor-support services, and non-medical health-management activities. During these periods, we also experienced growth in our customer base, increased accounts receivable associated with a higher volume of technical service activities, the introduction of inventory to support our PRC health-management operations, and higher general and administrative expenses relating to personnel, leased premises, and the build-out of our technology infrastructure.

Our U.S.-based advertising platform, <u>www.dazhong368.com</u>, continued to provide online advertising and profile-hosting services to professional service providers in the New York metropolitan area. We offer customers an "ID card introduction" page, which presents a personalized business profile, and we assist with maintaining and updating posted content. We believe this one-stop service model enhances user experience and improves customer acquisition and retention.

Among our PRC subsidiaries, Dao Ling Doctor (Zhejiang) Health Management Co., Ltd. ("Dao Ling Doctor Zhejiang") serves as our primary operating subsidiary and conducts substantially all of our revenue-generating activities in the PRC. Its primary business consists of providing technical development, technical-support, and platform-maintenance services to distributors of the "Dao Ling Doctor" brand, from which it earns technical-service fees.

A second PRC subsidiary, Dao Ling Doctor (Huzhou) Health Consulting Co., Ltd. ("Dao Ling Doctor Huzhou"), engages in early-stage development of non-medical health-consulting services (excluding diagnosis and treatment), network and information-security software development, big-data services, and related ancillary support functions. While Dao Ling Doctor Huzhou does not currently contribute a material portion of our revenue, it supports the development of future service lines and technology capabilities for the Dao Ling Doctor ecosystem.

[**Table of Contents**](#V_0000001)

**Products and Services**

Our current products and services consist of our U.S.-based online advertising and profile-hosting platform and the technical development, distributor-support, and non-medical health-management services conducted through our PRC subsidiaries operating under the "Dao Ling Doctor" brand. Through our website, <u>www.dazhong368.com</u>, we provide online advertising, website-development, and profile-hosting services primarily to professional individuals and small businesses in the New York metropolitan area. Customers use our platform to promote their services or products to their own end-users, and we offer each customer a personalized "ID card introduction" page that presents their business profile. We also assist customers in maintaining and updating the content posted on their pages. We continue to maintain and upgrade this platform to improve user experience and support the expansion of our customer base.

Our PRC subsidiaries provide technical development, technical-support, and platform-maintenance services to distributors of the "Dao Ling Doctor" brand, from which we earn service fees. These services include software development, system maintenance, distributor training support, and other technology-related functions associated with the Dao Ling Doctor service ecosystem. In addition, certain PRC subsidiaries engage in early-stage non-medical health-management and consulting activities, network and information-security software development, big-data services, and related support functions intended to complement and expand the technical-service capabilities offered to our distributor network.

**Strategy**

Our strategy is to expand the reach and capabilities of both our U.S. advertising platform and our PRC operations under the "Dao Ling Doctor" brand by growing our distributor network, increasing service volume, and strengthening the technical infrastructure that supports our platform. In the PRC, management intends to continue developing the Dao Ling Doctor ecosystem through the build-out of standardized service stores, the expansion of distributor-support systems, and the integration of AI-based tools, including data-driven health-management functions and digital-human service features. Management has also expressed long-term goals relating to large-scale store expansion in the PRC and the United States, broader development of non-medical health-management offerings, and the exploration of new initiatives such as cross-border duty-free retail functions and technology-driven community models, including potential Web3 or DAO-based membership concepts. These goals are aspirational and subject to significant uncertainties. In the United States, our focus remains on improving and maintaining our online advertising and content-hosting platform, offering customers personalized ID card introduction pages and ongoing content-update support to enhance the user experience and strengthen customer retention. Across both markets, our strategy is to support steady operational expansion, enhance service quality, and develop a broader network of users, distributors, and business partners.

**Competitive Conditions**

We operate in highly competitive industries in both the United States and the PRC. Our U.S. online advertising platform competes with numerous digital advertising providers, including online directories, local and regional advertising services, and large technology companies with significantly greater financial, technical and marketing resources, broader user bases, and stronger brand recognition. Many of these competitors are able to invest more heavily in product development, customer acquisition and pricing incentives, which may limit our ability to attract and retain customers or require us to reduce prices to remain competitive.

In the PRC, our Dao Ling Doctor subsidiaries compete in rapidly evolving markets for technical development services, platform maintenance, distributor-support services, and non-medical health-management activities. These markets include both large established technology companies and smaller regional service providers that may offer similar services with greater operational scale, more advanced technologies, or lower pricing. Competition in these sectors is driven by platform performance, technological capabilities, service quality, customer support and the ability to acquire and retain distributors and service partners.

Across all of our business lines, many competitors possess substantially greater financial and technical resources, longer operating histories, larger customer or distributor networks, and more recognized brand identities than we do. As a result, they may be able to adopt more aggressive pricing strategies, develop or deploy advanced technologies more quickly, and devote greater resources to marketing and customer support. While we believe our cost-effective service model, personalized customer support and developing proprietary technologies provide advantages, there can be no assurance that these factors will enable us to compete successfully or maintain or grow our market position.

[**Table of Contents**](#V_0000001)

**Proven and Experienced Management Team**

We are led by our Chief Executive Officer, Barry Wan, who also serves as our Chief Financial Officer, Treasurer, Secretary, and Chairman of the Board. Mr. Wan has overseen the Company's transition from a U.S.-based online advertising business to an organization operating both in the United States and through our Dao Ling Doctor subsidiaries in the PRC. He has played a central role in managing the development of our technical-service and health-management operations, coordinating our cross-border corporate structure, and supporting the expansion of our business activities. Although our management team operates a relatively small organization and has limited experience managing a publicly traded company, we believe that their operational involvement and familiarity with our service lines support our ability to continue building our business.

**Our Development Plan**

Our development plan focuses on expanding the technical-service and health-management capabilities of our PRC subsidiaries, strengthening the distributor network operating under the "Dao Ling Doctor" brand, and improving the functionality and user experience of our U.S. online advertising platform. In the PRC, management intends to continue developing standardized service stores, enhancing distributor-support systems, and integrating additional AI-enabled features, including data-driven health-management tools and digital-human technology. Management also plans to explore additional service lines such as cross-border duty-free retail functions and technology-driven community models, including preliminary Web3 or DAO-based concepts. These initiatives are at various stages of development and remain subject to significant uncertainties. In the United States, our efforts remain focused on maintaining and upgrading our advertising and profile-hosting platform to improve customer experience, support content management for users, and attract a broader base of small businesses and professional service providers. Overall, our development plan is intended to support steady operational growth, enhance the services available within the Dao Ling Doctor ecosystem, and expand our presence in both the PRC and U.S. markets.

**Expanding Business Operations**

 ****

Our business operations have continued to expand in both the PRC and the United States as we increase the scope of services offered under the "Dao Ling Doctor" brand and enhance the functionality of our online advertising platform. In the PRC, we have grown our technical-service activities, distributor-support functions, and non-medical health-management services, supported by investments in personnel, leased facilities, inventory, and technology infrastructure. Management intends to continue expanding the Dao Ling Doctor ecosystem through the development of additional standardized service locations, the use of AI-enabled tools, and the build-out of broader support capabilities for distributors and service providers. In the United States, we are continuing to improve our online platform to support customer acquisition and retention among small businesses and professional service providers who use our website to promote their services. As our operational footprint grows, we expect that the scale and complexity of our business activities will continue to increase across both markets.

 **Expand to New Geographic Markets**

 ****

We intend to expand our presence in additional geographic markets as our operational capabilities grow. In the PRC, management has outlined plans to broaden the Dao Ling Doctor service ecosystem through the development of additional distributor locations and standardized service stores in new provinces and municipalities, subject to regulatory, financial, and operational feasibility. Management has also expressed a long-term intention to establish a network of service locations in the United States, supported by our existing leased premises in New York and the continued build-out of our service infrastructure. In addition, certain early-stage initiatives being evaluated by management, such as cross-border duty-free retail functions, may require the Company to operate in additional regions or jurisdictions in the future. These geographic-expansion plans are preliminary, aspirational, and subject to significant uncertainties, including market conditions, regulatory approvals, and the availability of sufficient financial and operational resources.

[**Table of Contents**](#V_0000001)

**Expand Products Offerings**

We intend to expand our product and service offerings in both the United States and the PRC as we continue to develop the Dao Ling Doctor service ecosystem and improve the functionality of our online advertising platform. In the PRC, management is focused on enhancing and broadening the technical-service capabilities provided to distributors, including additional software development, AI-enabled tools, data-driven health-management functions, and expanded non-medical health-management and consulting services. Management is also evaluating early-stage initiatives such as cross-border duty-free retail functions and technology-driven community models that may create additional service categories in the future, although these initiatives remain preliminary and subject to uncertainty. In the United States, we plan to continue improving our online advertising and content-hosting platform by upgrading platform features, enhancing customer support, and developing additional tools to help small businesses and professional individuals promote their services more effectively. Across both markets, our goal is to expand the range of services available to users and distributors while maintaining flexibility to adapt to emerging customer preferences and evolving market conditions.

**Our Marketing**

Our marketing efforts are focused on increasing visibility for our online advertising platform in the United States and supporting the continued growth of the Dao Ling Doctor service ecosystem in the PRC. In the United States, we intend to promote our platform through online channels, direct outreach to small businesses and professional service providers, and the continued enhancement of the personalized ID card introduction pages offered to customers. We may also utilize local publications and community-based advertising where appropriate to reach potential users in the New York metropolitan area. In the PRC, our marketing activities are expected to rely primarily on the distributor network operating under the "Dao Ling Doctor" brand, as well as digital promotion, platform demonstrations, and training support provided to distributors and service partners. Across both markets, we expect that customer referrals, distributor relationships, and ongoing improvements to our platform functionality will contribute to increased awareness and user adoption of our services.

**Employees**

As of the date of this prospectus, we have 3 full-time employees, all of whom are employed by our PRC subsidiaries. We do not currently have any part-time employees or employees based in the United States.

**Environmental Laws**

Our operations are not subject to any environmental laws.

**Corporate Information**

Our Company does not own any real property and conducts all operations from leased facilities in the United States and the PRC.

In the United States, we lease office space at 133-27 39th Avenue, #PH2A, Flushing, New York 11354, under a lease that began in January 2025 and expires in December 2025, with monthly rent of $30,000 payable monthly. We also lease office space at 135-27 38th Avenue, Suite #388, Flushing, New York 11354, under a lease that began in January 2025 and expires in December 2025, with monthly rent of $10,000. In addition, our subsidiary Anti-aging Care LLC leases premises at 136-17 39th Avenue, GB-3, Flushing, New York 11354, under a lease commencing in October 2024 and ending in October 2031, with annual rent obligations following a one-year free-rent period from November 2024 through October 2025. In the PRC, Dao Ling Doctor (Hangzhou) Holding Co., Ltd. leases office space located on the 9th and 10th floors and Room 1002 of Building 1, Daofu Center, Huide Plaza, Xiaoshan District, Hangzhou, Zhejiang Province, under a lease from November 2023 to December 2025, with monthly rent of RMB 76,362. Dao Ling Doctor (Zhejiang) Health Management Co., Ltd. leases additional space on the 9th and 19th floors of the same building in Hangzhou under a lease also running from November 2023 to December 2025, with monthly rent of RMB 147,337. These leased facilities support our administrative functions, technical-service operations, distributor support, and our developing non-medical health-management activities. We feel these facilitis are sufficient for our purposes.

**Insurance**

We do not maintain any commercial insurance policies for our business or operations. Other than statutory social insurance contributions required for full-time employees of Dao Ling Doctor (Hangzhou) Holding Co., Ltd. and Dao Ling Doctor (Zhejiang) Health Management Co., Ltd., neither we nor any of our subsidiaries carry personal injury protection insurance, business interruption insurance, product liability insurance, directors and officers liability insurance, or key-man life insurance. As a result, we may be exposed to risks that could have a material adverse effect on our business, financial condition, and results of operations. See "Risk Factors—Risks Related to Our Business and Industry—We have limited insurance coverage with respect to our business and operations."

[**Table of Contents**](#V_0000001)

**Legal Proceedings**

There are no pending legal proceedings to which we are a party or in which any director, officer or affiliate of ours, any owner of record or beneficially of more than 5% of any class of our voting securities, or security holder is a party adverse to us or has a material interest adverse to us.

**MANAGEMENT'S DISCUSSION AND ANALYSIS**

**OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following discussion of the financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements appearing in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should read the "Risk Factors" section of this prospectus for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. The various sections of this discussion contain forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risk factors described throughout this prospectus as well as other matters over which we have no control. See "Cautionary Note Regarding Forward-Looking Statements." Our actual results may differ materially. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this prospectus.*

**Overview**

The Company operates an online advertising and profile-hosting business through its website, <u>www.dazhong368.com</u>, which primarily serves professional individuals and small businesses in the New York metropolitan area. Through this platform, we provide advertising services and personalized business profile pages and generate revenue from advertising fees paid by customers for the publication and maintenance of their content. Beginning in late 2023, we expanded our operations into the Asia-Pacific and Chinese markets through our Dao Ling Doctor subsidiaries, which provide technical development, platform maintenance, distributor-support services, and non-medical health-management services. These PRC subsidiaries have generated increasing revenues since the fourth quarter of 2024, reflecting growth in service volume, an expanding distributor network, and increased customer engagement. As a result, our operations now consist of both our legacy U.S. online advertising business and our developing PRC technical-services and health-management businesses.

**Liquidity and Capital Resources**

During the fiscal year ended December 31, 2024 and continuing into 2025, we funded a portion of our operations through the issuance of several promissory notes to multiple lenders. These included (i) a note issued to Barry Wan in the principal amount of $428,789.50, (ii) a note issued to New Lite Ventures LLC in the principal amount of $29,571.00, (iii) two notes originally issued by our PRC subsidiaries—Antiaging Doctor Hangzhou Holding Ltd. and Dao Ling Doctor (Zhejiang) Health Management Limited—to Hemeihui E-Commerce Co., Ltd., in the principal amounts of $538,568.00 and $287,174.00, respectively, and (iv) a note issued to Tairan Baohe Insurance Sales Co., Ltd. in the principal amount of $383,598.00. The Tairan Baohe note was subsequently repaid and is no longer outstanding.

In December 2025, we entered into four separate Assignment and Amendment of Promissory Note agreements with the holders or assignees of the outstanding notes other than the repaid Tairan Baohe note. Under these agreements, each applicable noteholder assigned its rights and interests in the notes to either Atlantic Equity Holdings Inc. or Empire Street Capital Inc., and the Company assumed all obligations under the notes through a full novation. The notes were further amended to provide for the automatic conversion of the outstanding principal balances into shares of our Class A common stock at a fixed conversion price of $0.30 per share. No additional proceeds were received by the Company in connection with these amendments. On November 25, 2025, the Board approved the issuance of the conversion shares, and upon such issuance, the applicable notes will be deemed fully satisfied and extinguished.

**Results of Operations for the Three Months Ended September 30, 2025 and 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2025** | **2024** | **$ Changed** | **% Changed** |
| Revenue | 390164 | 173174 | 216990 | 125.30% |
| Cost of revenues | 65691 | 14373 | 51318 | 357.04% |
| Selling, general and administrative expenses | 375695 | 356569 | 19126 | 5.36% |
| Loss from operations | (51222) | (197768) | 146546 | -74.10% |
| Other income | 69 | 22 | 47 | 213.64% |
| Net loss | (61598) | (197746) | 136148 | -68.85% |

---

During the three months ended September 30, 2025 and 2024, the Company generated revenues of $390,164 and $173,174, respectively. The increase in revenue was primarily due to continued growth of the Company's online platform technical operation support and maintenance services for the period which commenced in 2024. In addition, the Company's subsidiary Anti-Aging Care LLC began limited operations during the three months ended September 30, 2025 which contributed to the overall increase in revenues for the current period.

Cost of revenues was $65,691 and $14,373 for the three months ended September 30, 2025 and 2024, respectively. Gross profit increased to $324,473 (gross margin of 83.16%) for the three months ended September 30, 2025, as compared to gross profit of $158,801 (gross margin of 91.70%) for the three months ended September 30, 2024. The change in gross margin is primarily due to the shift in revenue streams to technical support and maintenance services business, which carries a different cost structure.

The Company incurred operating expenses of $375,695 and $356,569 for the three months ended September 30, 2025 and 2024, respectively. The increase in operating expenses was mainly due to the increase rental and facility costs.

For the three months ended September 30, 2025 and 2024, the Company's other income was $69 and $22, respectively, which consisted of interest income.

For the three months ended September 30, 2025, our net loss was $61,598 comparing to a net loss of $197,746 for the three months ended September 30, 2024. The decrease in net loss is mainly due to the increased revenues.

**Results of Operation for the six months ended September 30, 2025 and 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2025** | **2024** | **$ Changed** | **% Changed** |
| Revenue | 681602 | 375243 | 306359 | 81.64% |
| Cost of revenues | 122397 | 14538 | 107859 | 741.91% |
| Selling, general and administrative expenses | 748630 | 772406 | (23776) | -3.08% |
| Loss from operations | (189425) | (411701) | 222276 | -53.99% |
| Other income | 10900 | 47 | 10853 | 23091.49% |
| Net loss | (194970) | (411654) | 216684 | -52.64% |

---

During the six months ended September 30, 2025 and 2024, the Company generated revenues of $681,602 and $375,243, respectively. The increase in revenue was primarily due to continued growth of the Company's online platform technical operation support and maintenance services for the period, which commenced in 2024. which accounted for the entire revenue for the current period. In addition, the Company's subsidiary Anti-Aging Care LLC began limited operations during the three months ended September 30, 2025 which contributed to the overall increase in revenues for the current period.

[**Table of Contents**](#V_0000001)

Cost of revenues was $122,397 and $14,538 for the six months ended September 30, 2025 and 2024, respectively. Gross profit increased to $559,205 (gross margin of 82.04%) for the six months ended September 30, 2025, as compared to gross profit of $360,705 (gross margin of 96.13%) for the six months ended September 30, 2024.

The change in gross margin is primarily due to the shift in revenue streams to technical support and maintenance services business, which carries a different cost structure.

The Company incurred operating expenses of $748,630 and $772,406 for the six months ended September 30, 2025 and 2024, respectively. The decrease in operating expenses was mainly due to the decrease in employee wages and benefits and legal and professional fees.

For the six months ended September 30, 2025, the Company received renovation subsidy of $10,810, which was recognized as other income, along with interest income.

For the six months ended September 30, 2025, our net loss was $194,970 comparing to a net loss of $411,654 for the six months ended September 30, 2024. The decrease in net loss is mainly due to the increased revenues and increase of other income.

**Equity and Capital Resources**

As of September 30, 2025, we had an accumulated deficit of $1,604,682 and working capital of $23,279, compared to accumulated deficit of $1,409,712 and a working capital of $132,689 as of March 31, 2025.

The decrease in the working capital was primarily driven by the increases in accounts receivables offset by the increase in operating lease liabilities – current portion and due to related parties, which impacted available cash.

The Company's net loss was partially offset by non-cash expenses, including $79,784 in depreciation and amortization, and $197,511 in amortization related to right-of-use (ROU) assets, mainly associated with leased office and retail spaces and leasehold improvements. Additionally, an increase of accounts receivables of $376,353 and an increase in inventories of $72,250 affected net cash used in operating activities for the six months ended September 30, 2025.

During the six months ended September 30, 2025 and 2024, the Company purchased fixed assets totaling $163,441 and $44,820, respectively.

During the six months ended September 30, 2025 and 2024, the Company received advances of $340,000 and $138,745 from related parties for working capital purposes, which shareholders are prepared to provide additional funding as needed.

As of September 30, 2025, we held approximately $455,446 in cash and cash equivalents. Our liabilities are primarily funded by shareholder loans and unrelated parties' loans, which do not require immediate repayment. Operations are continuing as usual, and management is committed to implementing expense control measures in the near term to support liquidity.

**Results of Operation for the years ended March 31, 2025 and 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2025** | **2024** | **$ Changed** | **% Changed** |
| Revenue | 817898 | 7499 | (810399) | 10806.76% |
| Cost of revenues | 389381 | 771 | 388610 | 50403.37% |
| Selling, general and administrative expenses | 1218476 | 419745 | 798731 | 190.29% |
| Other income (loss) | 69550 | 46 | 69504 | 151095.65% |
| Loss from operations | (789959) | (413017) | (376942) | 91.27% |
| Net loss | (720409) | (412971) | (307438) | 74.45% |

---

[**Table of Contents**](#V_0000001)

During the years ended March 31, 2025 and 2024, the Company generated revenues of $817,898 and $7,499, respectively. The increase in revenue was primarily due to the launch and provision of online platform technical operation support and maintenance services, which accounted for the entire revenue for the year; as compared to $nil in same period in 2024. In contrast, revenue for the year ended March 31, 2024, which was derived from health and beauty product sales and online advertising in the amount of $7,499. The Company did not generate any revenue from health and beauty product sales and online advertising for the year ended March 31, 2025.

Cost of revenues was $389,381 and $771 for the years ended March 31, 2025 and 2024, respectively. Gross profit increased to $428,517 (gross margin of 52.4%) for the year ended March 31, 2025, as compared to gross profit of $6,728 (gross margin of 89.7%) for the year ended Macrh3 1, 2024. The change in gross margin is primarily due to the shift in revenue streams and the commencement of the new technical support and maintenance services business in 2025, which carries a different cost structure.

The Company incurred operating expenses of $1,218,476 and $419,745 for the years ended March 31, 2025 and 2024, respectively. The increase in operating expenses was mainly due to the increase in rental expenses and employee wages and benefits, relating to the Company's initiative for business expansion and additional revenue stream. The Company also incurred start-up costs such as cloud hosting expenses, development and maintenance costs in pursuit of its business plan.

For the year ended March 31, 2025, the Company received renovation subsidy of $69,471, which was recognized as other income, along with interest income of $79.

For the year ended March 31, 2025, our net loss was $720,409 comparing to a net loss of $412,971 for the year ended March 31, 2024. The increase in net loss is mainly due to the increased operating expenses.

**Equity and Capital Resources**

As of March 31, 2025, we had an accumulated deficit of $1,409,712 and working capital of $132,689, compared to accumulated deficit of $689,303 and a working capital deficit of $647,227 as of March 31, 2024.

The increase in the working capital was primarily driven by the conversion of certain due on demand debts into long-term notes payable, along with increases in other receivables and current assets. Additionally, there was a rise in accounts receivable and advances to suppliers offset by decrease in operating lease liabilities which impacted available cash.

The Company's net loss was partially offset by non-cash expenses, including $144,271 in depreciation and amortization, and $330,671 in amortization related to right-of-use (ROU) assets, mainly associated with leased office and retail spaces and leasehold improvements.

During the years ended March 31, 2025 and 2024, the Company purchased fixed assets and intangible assets totaling $63,345 and $224,248, respectively.

During the years ended March 31, 2025 and 2024, the Company received advances of $364,303 and $616,866 from related parties for working capital purposes, which shareholders are prepared to provide additional funding as needed. The Company also borrowed $803,734 and $423,209 from an unrelated third party during the years ended March 31, 2025 and 2024, respectively. On December 31, 2024, a total of $1,284,103 debt owed to related party and third party were converted into long-term notes payable, representing a non-cash financing activity. On March 31, 2025, the Company entered into Tripartite Debt Assignment Agreements with Mr. Barry Wan (a related party) and the unrelated third-party original lender, pursuant to which certain loans and notes totaling $1,216,440 were legally assigned to Mr. Wan.

[**Table of Contents**](#V_0000001)

As of March 31, 2025, we held approximately $370,549 in cash and cash equivalents. Our liabilities are primarily funded by shareholder loans and unrelated parties' loans, which do not require immediate repayment. Operations are continuing as usual, and management is committed to implementing expense control measures in the near term to support liquidity.

**Going Concern Assessment**

The Company demonstrates adverse conditions that raise substantial doubt about the Company's ability to continue as a going concern. These adverse conditions are negative financial trends, specifically cash outflow from operating activities, operating losses, accumulated deficit and other adverse key financial ratios.

Management's plan to alleviate the substantial doubt about the Company's ability to continue as a going concern include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations and execute the business plan of the Company in order to meet its operating needs on a timely basis. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company's ongoing capital expenditures and other requirements.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

**Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

**Critical Accounting Policies**

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management's application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions included in footnote 2 of our financial statements is critical to an understanding of our financial statements.

[**Table of Contents**](#V_0000001)

**MANAGEMENT**

**Executive Officers and Directors**

The following table sets forth information about our executive officers and directors as of the date of this prospectus:

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position** |
| Barry Wan | 49 | President, Chief Executive Officer, Chief Financial Officer and sole director |

---

*Barry Wan* has served as the Chief Executive Officer, President and Chief Financial Officer of our Company since June 2023. Mr. Wan is a seasoned entrepreneur who has made significant contributions to the science and technology, real estate, and insurance sectors in both the United States and China. In the 2000s, he successfully established multiple companies in the U.S., including REMAX People Realty, where he served as the founder and CEO. Under his leadership, REMAX People Realty has become one of the leading real estate brokerage firms in New York City.

In 2010, Mr. Wan expanded his entrepreneurial endeavors into China. Mr. Wan founded Ymall, an innovative ecommerce 2.0 platform catering to both online and physical retailers. Additionally, he established Anti-Age Dr. and Tai Bao Global Ecological NewWealth.

Furthermore, Mr. Wan has also contributed his expertise as a Strategy Consultant for Renmi (Hangzhou) Network Technology Co., Ltd. and held the esteemed position of Executive Chairman at the China Real Estate Chamber of Commerce. Mr. Wan received his bachelor's degree in Science from The Hefei University of Technology, followed by a Master's degree from Queens College, the City University of New York.

Mr. Wan is well qualified to serve on our board of directors due to his significant experience in the real estate and commerce industries.

**Code of Ethics**

Effective upon consummation of this offering, we will adopt a code of ethics that applies to all of our executive officers, directors, and employees. The code of ethics codifies the business and ethical principles that govern all aspects of our business.

**Director Agreements and Indemnification Agreements**

None.

**Board of Directors**

Our directors hold office until the next annual meeting of shareholders of the Company and until their successors have been elected and qualified. Our officers are elected by the board of directors and serve at the discretion of the board of directors.

**Director Independence**

We evaluate independence by the standards for director independence set forth in the Nasdaq Marketplace Rules. Under such rules, our only board member is not independent.

**Committees of our Board of Directors**

We currently have no committees. Rather, the functions typically associated with auditing and other such committees are performed by our sole director.

**Share Incentive Plan**

We currently do not have any stock incentive plans.

**Family Relationships**

There are no family relationships among the directors and executive officers of our company.

**Involvement in legal proceedings**

There are no legal proceedings that have occurred within the past ten years concerning our directors, or control persons which involved a criminal conviction, a criminal proceeding, an administrative or civil proceeding limiting one's participation in the securities or banking industries, or a finding of securities or commodities law violations.

[**Table of Contents**](#V_0000001)

**EXECUTIVE COMPENSATION**

**Summary Compensation Table**

The following Summary Compensation Table provides certain summary information concerning the compensation of our officers and directors.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Name and Principal Position | Year | Salary ($) | Bonus ($) | Stock Awards ($) | Option Awards ($) | Non-Equity Incentive Plan Compensation ($) | Change in Pensions Value and Nonqualified Deferred Compensation Earnings ($) | All Other Compensation ($) | Total ($) |
| Dingshan Zhang, Chief Executive Officer / Chief Financial Officer <sup>(1)</sup> | 2023 |  |  |  |  |  |  |  |  |
|  | 2022 |  |  |  |  |  |  |  |  |
| Jing Wan, Chief Executive Officer / Chief Financial Officer <sup>(2)</sup> | 2023 |  |  |  |  |  |  |  |  |
| Barry Wan, Chief Executive Officer / Chief Financial Officer <sup>(3)</sup> | 2024 |  |  |  |  |  |  |  |  |
|  | 2023 |  |  |  |  |  |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Mr.
 Zhang resigned as a Director, President, CEO and CFO of the Company on April 10, 2023.

(2) Ms.
 Wan resigned as a Director, President, CEO and CFO of the Company on June 16, 2023.

(3) Mr.
 Wan was appointed as a Director, President, CEO and CFO of the Company on June 16, 2023

[**Table of Contents**](#V_0000001)

**Employment Agreements**

We do not currently have employment agreements with our officers.

**Director Compensation**

There is currently no agreement or arrangement to pay any of our directors for their services as directors.

**Pension Benefits**

We currently do not maintain any pension plan or arrangement under which our named executive officers are entitled to participate or receive post-retirement benefits.

**Limitation on Liability and Indemnification Matters**

The Company indemnifies directors, officers, employees and agents, and the heirs of personal representatives of such persons, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgement, actually and reasonably incurred by such person arising out of their function as a director, officer, employee or agent to the Company.

*Limitation of Liability of Directors*

Section 402(b) of the BCL permits a New York corporation to include in its certificate of incorporation a provision eliminating the potential monetary liability of a director to the corporation or its shareholders for breach of fiduciary duty as a director; provided that this provision may not eliminate the liability of a director (i) for acts or omissions in bad faith or which involve intentional misconduct or a knowing violation of law, (ii) for any transaction from which the director receives an improper personal benefit or (iii) for any acts in violation of Section 719 of the BCL. Section 719 provides that a director who votes or concurs in a corporate action will be liable to the corporation for the benefit of its creditors and shareholders for any damages suffered as a result of an action approving (i) an improper payment of a dividend, (ii) an improper redemption or purchase by the corporation of shares of the corporation, (iii) an improper distribution of assets to shareholders after dissolution of the corporation without adequately providing for all known liabilities of the corporation or (iv) the making of an improper loan to a director of the corporation. Our restated certificate of incorporation, as amended, provides that our directors shall not be liable to us or our shareholders for a breach of their duties to the fullest extent in which elimination or limitation of the liability of directors is permitted by the BCL.

*Indemnification of Officers and Directors*

Our restated certificate of incorporation, as amended, provides that we shall indemnify and hold harmless, to the fullest extent permitted by the BCL, each person (and their heirs, executors, or administrators) who was or is a party or is threatened to be made a party to, or is involved in, any civil, criminal, administrative or investigative action, suit or proceeding, by reason of the fact that such person is or was a director or officer of our Company or is or was serving at our request as a director or officer of another corporation, partnership, joint venture, trust or other enterprise. We are also obligated to pay the cost of the expenses incurred by our officers and directors (including attorney's fees) in defending themselves in such proceedings in advance of final disposition if the officer or director agrees to repay the amount advanced in the event it is ultimately determined that the officer or director was not entitled to be indemnified by us as authorized by our restated certificate of incorporation, as amended. We are not obligated to indemnify any director or officer (or his or her heirs, executors or administrators) in connection with a proceeding initiated by such person unless the proceeding was authorized or consented to by our Board. We have entered into indemnification agreements with each of our current directors to effectuate the indemnification provisions of our restated certificate of incorporation, as amended.

**SEC Position on Indemnification for Securities Act Liabilities**

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.

[**Table of Contents**](#V_0000001)

**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The following table sets forth information about the beneficial ownership of our Common Stock at the date of this prospectus by:

● each person or entity who is known by us to own beneficially more than 5% of our outstanding capital stock;

● each of the persons named in the Summary Compensation Table;

● each of our directors; and

● all of our directors and executive officers as a group.

Beneficial ownership is determined in accordance with the rules of the SEC. Each stockholder's percentage of beneficial ownership as of November 25, 2025 set forth in the following table is based on 34,275,342 shares of our Common Stock outstanding at the date of this prospectus.

Unless otherwise indicated, the principal address of each of the stockholders below is c/o Antiaging Quantum Living Inc., 135-27 38th Avenue, #388, Flushing, NY 11354. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of Common Stock held by them.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Title of Class** | **Name and Address**<br> **Of Beneficial Owner** | **Position** | **Amount and Nature**<br> **Of Beneficial Ownership** | **Percent**<br> **Of Class<sup>(1)</sup>** |
| Class A Common Stock | New Lite Ventures LLC, 133-27 39th Ave, Flushing, NY 11354 |  | 29215000 | 85.21% |
| Class A Common Stock | Atlantic Equity Holdings Inc., 8 The Green, Ste R <br>Dover, DE 19901 |  | 1893796<sup>(3)</sup> | 5.53% |
| Class A Common Stock | Empire Street Capital Inc., 136-20 38TH AVENUE, STE 3D, FLUSHING, NY, UNITED STATES, 11354 |  | 2386544<sup>(2)</sup> | 6.96% |
| Class A Common Stock | Barry Wan, CEO, CFO and Director, 133-27 39th Ave, Flushing, NY 11354 <sup>(3)</sup> |  | 0<sup>(4)</sup> | 0% |
| Class A Common Stock | All Officers and Directors <br> As a Group (1 person) |  | 0 | 0% |

---

(1) Based on 34,275,342 shares of Class A Common Stock outstanding as of November 25, 2025.

(2) Includes 2,386,544 shares issued to Empire Street Capital Inc. upon conversion of the Barry Wan and Zhejiang Notes.

(3) Includes 1,893,796 shares issued to Atlantic Equity Holdings Inc. upon conversion of the New Lite and Hangzhou Notes.

(4) Mr. Barry Wan may be deemed to beneficially own New Lite Ventures LLC, which he wholly owns.

\* Beneficial ownership is determined in accordance with the rules of the SEC that generally attribute beneficial ownership of securities to persons who possess sole or shared voting power and/or investment power with respect to those securities. Common Stock subject to options or warrants that are currently exercisable or exercisable within 60 days of the date of this prospectus are deemed to be outstanding and to be beneficially owned by the person or group holding such options or warrants for the purpose of computing the percentage ownership of such person or group but are not treated as outstanding for the purpose of computing the percentage ownership of any other person or group. Unless otherwise indicated, voting and investment power are exercised solely by the person named above or shared with members of such person's household.

\*\* Percent of class is calculated on the basis of the number of shares outstanding on the date of this prospectus plus the number of shares the person has the right to acquire within 60 days of the date of this prospectus.

[**Table of Contents**](#V_0000001)

**CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS**

**Related Party Transactions**

In August 2019, the Company borrowed $71,000 from the former President of the Company, Mr. Dingshan Zhang, which bears no interest with a maturity in December 2021. During the year ended March 31, 2022, the Company repaid $17,000 to Mr. Zhang. In May 2021 the Company borrowed an additional $5,000 from Mr. Zhang. On December 29, 2021, the Company and Mr. Zhang verbally amended the loan agreement and extended the maturity date to December 31, 2023. During the year ended March 31, 2023, the Company received an additional loan in the total amount of $24,300 from, Mr. Zhang.

Upon consummation of the change of control which resulted from that certain securities purchase agreement entered into on April 10, 2023, the balance of the $83,300 shareholder loan was waived by Mr. Zhang in its entirety, which was recognized as an equity transaction with the shareholder.

During the years ended March 31, 2024, the Company received advances in the total amount of $613,843 from Mr. Wan, our Chief Executive Officer, for working capital purposes. The loan is unsecured, non-interest-bearing and due on demand. The amount due to Mr. Wan was $613,843 and $nil as of March 31, 2024 and 2023.

In December 2024, the Company issued four unsecured, non-interest-bearing promissory notes: (i) a note in the principal amount of $428,789.50 issued to Mr. Barry Wan, the Company's Chief Executive Officer and a director; (ii) a note in the principal amount of $29,571.00 issued to New Lite Ventures LLC, an entity wholly owned and controlled by Mr. Wan; and (iii) two notes in the principal principal amounts of $287,174 and $538,568, respectively, issued by the Company's PRC subsidiaries—Dao Ling Doctor (Zhejiang) Health Management Limited and Antiaging Doctor Hangzhou Holding Ltd.—to Hemeihui E-Commerce Co., Ltd. None of these notes contained conversion features at the time of issuance.

In November 2025, the Company entered into an Assignment and Amendment of Promissory Note with respect to each outstanding note. Each amendment provided for the automatic conversion of the full principal amount of the applicable note into shares of Class A Common Stock at a fixed conversion price of $0.30 per share. No additional consideration was received by the Company in connection with these amendments.

Immediately prior to conversion, each original noteholder assigned its amended note to a third-party assignee with the Company's consent. As a result, the original related-party lenders (i.e., Mr. Wan, New Lite Ventures LLC, and Hemeihui E-Commerce Co., Ltd.) did not receive any shares upon conversion. Following these assignments, the amended notes automatically converted into an aggregate of 4,280,340 shares of Class A Common Stock, consisting of: (i) 1,893,796 shares issued to Atlantic Equity Holdings Inc. upon conversion of the notes originally issued to New Lite Ventures LLC and Antiaging Doctor Hangzhou Holding Ltd.; and (ii) 2,386,544 shares issued to Empire Street Capital Inc. upon conversion of the notes originally issued to Mr. Wan and Dao Ling Doctor (Zhejiang) Health Management Limited.

[**Table of Contents**](#V_0000001)

**DESCRIPTION OF CAPITAL STOCK**

The following description of our capital stock is only a summary and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws, which have been filed as exhibits to the registration statement of which this prospectus forms a part.

Our authorized capital stock consists of 6,000,000,000 shares of Common Stock, par value $0.00001 per share, divided into 1,200,000,000 shares each of Class A, Class B, Class C, Class D, and Class E Common Stock..

Authorized and Issued Stock

---

| | | | |
|:---|:---|:---|:---|
| | **Number of shares at December 5, 2025** | **Number of shares at December 5, 2025** | **Number of shares at December 5, 2025** |
| <br>**Title of Class** | **Authorized** | **Issued and<br> Outstanding** | **Reserved** |
| Class A Common Stock, $0.00001 par value per share | 1200000000 | 34275342 \* | 0 |
| Class B Common Stock, $0.00001 par value per share | 1200000000 | 0 | 0 |
| Class C Common Stock, $0.00001 par value per share | 1200000000 | 0 | 0 |
| Class D Common Stock, $0.00001 par value per share | 1200000000 | 0 | 0 |
| Class E Common Stock, $0.00001 par value per share | 1200000000 | 0 | 0 |

---

\* The 34,275,342 Class A shares outstanding include 4,280,340 shares issued on November 25, 2025 upon conversion of four promissory notes.

**Class A Common Stock**

*Dividends*. Each share of our Common Stock is entitled to receive an equal dividend, if one is declared. We cannot provide any assurance that we will declare or pay cash dividends on our Common Stock in the future. Any future determination to declare cash dividends will be made at the discretion of our board of directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors may deem relevant. Our board of directors may determine it to be necessary to retain future earnings (if any) to finance our growth. See "Risk Factors" and "Dividend Policy."

*Liquidation*. If our company is liquidated, then assets that remain (if any) after the creditors are paid and the owners of preferred stock receive liquidation preferences (as applicable) will be distributed to the owners of our Common Stock *pro rata*.

*Voting Rights*. Each share of our Common Stock entitles the owner to one vote. All matters are decided by majority vote other than as required by law and the election of directors. A plurality of votes is sufficient to elect a director at a meeting; election by written consent to fill a vacancy, however, requires a majority vote. There is no cumulative voting.

*Preemptive Rights*. Owners of our Common Stock have no preemptive rights. We may sell or issue shares of our Common Stock to third parties without first offering such shares to current stockholders. On November 25, 2025, our majority stockholder approved, by written consent, the issuance of 4,280,340 shares of our Class A Common Stock upon the automatic conversion of the Company's amended promissory notes and waived any preemptive or similar rights with respect to such issuance.

*Redemption Rights.* We do not have the right to buy back shares of our Common Stock except in extraordinary transactions, such as mergers and court approved bankruptcy reorganizations. Owners of our Common Stock do not ordinarily have the right to require us to buy their Common Stock. We do not have a sinking fund to provide assets for any buy back.

*Conversion Rights*. Shares of our Common Stock cannot be converted into any other kind of stock except in extraordinary transactions, such as mergers and court approved bankruptcy reorganizations.

*Nonassessability*. All outstanding shares of our Common Stock are fully paid and nonassessable.

[**Table of Contents**](#V_0000001)

**Classes B, C, D and E Common Stock**<br>

Our certificate of incorporation authorizes 1,200,000,000 shares each of Class B, Class C, Class D and Class E Common Stock, par value $0.00001 per share. As of November 25, 2025, no shares of Class B, Class C, Class D or Class E Common Stock are issued and outstanding, and we have not designated or established any specific rights, preferences or privileges for these classes beyond those applicable to our Common Stock generally. We currently have no present plans to issue any shares of Class B, Class C, Class D or Class E Common Stock.

**New York Anti-Takeover Statutes**

Section 912 of the New York Business Corporation Law (the "BCL"), prohibits a New York corporation from engaging in certain business combinations with an interested shareholders and prevents certain persons from making a takeover bid for a New York corporation unless certain prescribed requirements are satisfied, or there is an exception. We are excepted from the provisions of Section 912 of the BCL because our shares of Common Stock are registered under Section 12 of the Securities Exchange Act of 1934.

**SELLING STOCKHOLDERS**

The Shares being offered by the Selling Stockholders are the shares of our Class A Common Stock issued to them in December 2025 upon the automatic conversion of certain amended promissory notes following assignments of those notes to the Selling Stockholders. We are registering the Shares to permit the Selling Stockholders to resell the Shares from time to time. Except for their ownership of the Shares described in this prospectus, the Selling Stockholders have not had any material relationship with us or our affiliates within the past three years.

Beneficial ownership is determined in accordance with Rule 13d-3(d) under the Exchange Act. The percentage of shares beneficially owned prior to this offering is based on 34,275,340 shares of Class A Common Stock outstanding as of November 25, 2025, which includes the 4,280,340 shares issued upon conversion of the amended promissory notes. Beneficial ownership is determined in accordance with Rule 13d-3(d) under the Exchange Act. The percentage of shares beneficially owned prior to this offering is based on 34,275,340 shares of Common Stock outstanding as of November 25, 2025 (which includes the 4,280,340 Conversion Shares issued upon the automatic conversion of the amended promissory notes).

None of the Selling Stockholders are a registered broker-dealer or an affiliate of a registered broker-dealer. The Selling Stockholders acquired the Shares in the ordinary course of business and not with a view to, or for, resale or distribution..

The Shares being registered for resale were issued by the Company on November 25, 2025 upon the automatic conversion of amended promissory notes at a fixed conversion price of $0.30 per share, following assignments of the amended notes to the Selling Stockholders. The original promissory notes, issued in December 2024 for an aggregate principal amount of $1,284,102.50, were unsecured, non-interest-bearing loan obligations when issued and did not include any conversion rights. The Company did not receive any additional consideration in connection with the amendments, assignments, or conversions, and the Shares were issued solely to the Selling Stockholders.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Number of<br> Shares of<br> Common Stock<br> Beneficially<br> Owned<br> Before the<br> Offering<sup>(1)</sup>** | <br>**% of Outstanding Shares Before the Offering<sup>(1)</sup>** | **Number of<br> Shares of<br> Common Stock Being<br> Offered<sup>(2)</sup>** | **Shares of<br> Common Stock <br> Beneficially<br> Owned<br> After the<br> Offering<sup>(1)</sup>** | **Percentage<br> Beneficially<br> Owned After<br> the Offering** |
| Atlantic Equity Holdings Inc. | 1893796 | 5.53% | 1893796 |  |  |
| Empire Street Capital Inc. | 2386544 | 6.96% | 2386544 |  |  |
| **TOTAL** | 4280340 | 12.49% | 4280340 |  |  |

---

(1) Beneficial
 ownership is calculated in accordance with Rule 13d-3 under the Exchange Act. Percentages in the column "Shares Beneficially
 Owned Before the Offering" are based on 34,275,340 shares of Class A Common Stock outstanding as of November 25, 2025.

(2) The
 Selling Stockholders acquired the shares of Class A Common Stock on November 25, 2025, upon the automatic conversion of amended promissory
 notes at a fixed conversion price of $0.30 per share, pursuant to separate Assignment and Amendment of Promissory Note agreements.

[**Table of Contents**](#V_0000001)

**PLAN OF DISTRIBUTION**

The Selling Stockholders will be offering the shares of Common Stock being covered by this prospectus at a fixed price of $0.30 per share.

The Selling Stockholders may use any one or more of the following methods when disposing of shares:

● ordinary brokerage transactions and transactions in which the broker-dealer solicits investors;

● block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;

● purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

● an exchange distribution in accordance with the rules of the applicable exchange;

● privately negotiated transactions;

● to cover short sales made after the date that the registration statement of which this prospectus is a part is declared effective by the Securities and Exchange Commission;

● broker-dealers may agree with the selling stockholder to sell a specified number of shares at a stipulated price per share;

● a combination of any of such methods of sale; and

● any other method permitted under applicable law.

The Selling Stockholders may also sell securities under Rule 144 under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.

In connection with the sale of the securities covered hereby, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

[**Table of Contents**](#V_0000001)

The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be "underwriters" within the meaning of the Securities Act in connection with such sales and they will be subject to the prospectus delivery requirements of the Securities Act. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. We are requesting that each selling stockholder inform us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. We will pay certain fees and expenses incurred by us incident to the registration of the securities.

Because the Selling Stockholders may be deemed to be an "underwriter" within the meaning of the Securities Act, they will be subject to the prospectus delivery requirements of the Securities Act, including Rule 172 thereunder. In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than under this prospectus. Retention by a selling stockholder of an underwriter would constitute a material change to our plan of distribution requiring a post-effective amendment.

We intend to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for us to be in compliance with the current public information requirement under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. We will use reasonable efforts to keep the registration statement effective for sufficient time for the identified selling stockholders to sell their Shares. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.

Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the selling stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and are informing the Selling Stockholders of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

**DISCLOSURE OF SEC POSITION ON**

**INDEMNIFICATION FOR SECURITIES ACT LIABILITIES**

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is therefore unenforceable.

In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director or officer of ours in the successful defense of the action, suit or proceeding) is asserted by the director or officer in connection with securities which may have been registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court or appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issues.

**LEGAL MATTERS**

The validity of the Shares covered by the registration statement of which this prospectus is a part has been passed upon for us by Celine and Partners, PLLC.

**EXPERTS**

The financial statements for the fiscal years ended March 31, 2025 and March 31, 2024 were audited by J&S Associate PLT and PWN LLP, respectively, each an independent registered public accounting firm, to the extent and for the periods set forth in their reports appearing elsewhere herein, and such financial statements are included in reliance upon those reports given upon the authority of said firms as experts in auditing and accounting.

[**Table of Contents**](#V_0000001)

**ENFORCEABILITY OF CIVIL LIABILITIES**

Our Chief Executive Officer is a Chinese citizen and resident. As such, a substantial portion of her assets are located outside the United States. As a result, it may be difficult or impossible for a shareholder to effect service of process within the United States upon us or these persons, or to enforce against us or them judgments obtained in United States courts, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States. It may also be difficult for shareholder to enforce judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our executive officers and directors.

We have appointed Celine & Partners PLLC as our agent upon whom process may be served in any action brought against us under the securities laws of the United States.

There is uncertainty as to whether the courts of the China, respectively, would:

● recognize or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States; or

● entertain original actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States.

There is uncertainty as to whether PRC courts would (i) recognize or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States, or (ii) entertain original actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States. The PRC Civil Procedures Law governs the recognition and enforcement of foreign judgments. PRC courts may recognize and enforce foreign judgments in accordance with the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made or on principles of reciprocity between jurisdictions. The PRC does not have any treaties or other agreements with the United States that provide for the reciprocal recognition and enforcement of foreign judgments. According to the PRC Civil Procedures Law, courts in the PRC will not enforce a foreign judgment against us or our directors and officers if they determine that the judgment violates the basic principles of PRC law or national sovereignty, security or public interest. As a result, it is uncertain whether a PRC court would enforce a judgment rendered by a court in the United States. Under the PRC Civil Procedures Law, foreign shareholders may originate actions based on PRC law against us in the PRC, if they can establish sufficient nexus to the PRC for a PRC court to have jurisdiction, and meet other procedural requirements, including, among others, the plaintiff must have a direct interest in the case, and there must be a concrete claim, a factual basis and a cause for the suit. It will be difficult for U.S. shareholders to originate actions against our Chief Financial Officer in China in accordance with PRC laws, and it will be difficult for U.S. shareholders, by virtue only of holding our Common Stock, to establish a connection to China for a PRC court to have jurisdiction as required under the PRC Civil Procedures Law.

It may also be difficult for you or overseas regulators to conduct investigations or collect evidence within China. For example, in China, there are significant legal and other obstacles to obtaining information needed for shareholder investigations or litigation outside China or otherwise with respect to foreign entities. Although the authorities in China may establish a regulatory cooperation mechanism with its counterparts of another country or region to monitor and oversee cross-border securities activities, such regulatory cooperation with the securities regulatory authorities in the U.S. may not be efficient in the absence of a practical cooperation mechanism. Furthermore, according to Article 177 of the PRC Securities Law, or "Article 177," which became effective in March 2020, no overseas securities regulator is allowed to directly conduct investigations or evidence collection activities within the territory of the PRC. Article 177 further provides that Chinese entities and individuals are not allowed to provide documents or materials related to securities business activities to foreign agencies without prior consent from the securities regulatory authority of the PRC State Council and the competent departments of the PRC State Council. While the detailed interpretation of or implementing of rules under Article 177 have to be promulgated, the inability of an overseas securities regulator to directly conduct investigation or evidence collection activities within China may further increase the difficulties faced by you in protecting your interests.

[**Table of Contents**](#V_0000001)

**INTERESTS OF NAMED EXPERTS AND COUNSEL**

Neither the named experts nor counsel own any of shares of our Common Stock.

**ADDITIONAL INFORMATION**

We will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information may be inspected and copied at the public reference facilities maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549 and at the SEC's regional offices located at the Northwestern Atrium Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661 and 233 Broadway, New York, New York 10279. You can obtain copies of these materials from the Public Reference Section of the SEC upon payment of fees prescribed by the SEC. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC's Web site contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of that site is http://www.sec.gov.

We have filed a registration statement on Form S-1 with the SEC under the Securities Act of 1933, as amended, with respect to the securities offered in this prospectus. This prospectus, which is filed as part of a registration statement, does not contain all of the information set forth in the registration statement, some portions of which have been omitted in accordance with the SEC's rules and regulations. Statements made in this prospectus as to the contents of any contract, agreement or other document referred to in this prospectus are not necessarily complete and are qualified in their entirety by reference to each such contract, agreement or other document that is filed as an exhibit to the registration statement. The registration statement may be inspected without charge at the public reference facilities maintained by the SEC, and copies of such materials can be obtained from the Public Reference Section of the SEC at prescribed rates. You may obtain additional information regarding our company on our website, located at www.dazhong368.com.

FINANCIAL STATEMENTS AND FOOTNOTES TO BE ADDED BY PRINTER

[**Table of Contents**](#V_0000001)

**PART II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 13. Other Expenses of Issuance and Distribution.**

We are paying all expenses of the offering. The following table sets forth all expenses to be paid by the registrant. All amounts shown are estimates except for the registration fee.

---

| | |
|:---|:---|
| SEC Registration Fee | $189.47 |
| Legal Fees and Expenses\* | $35000 |
| Accounting Fees and Expenses\* | $15000 |
| Miscellaneous Fees\* | $5000 |
| Total | $55189.47 |

---

\* Estimated

**Item 14. Indemnification of Directors and Officers.**

The Company indemnifies against all expenses, including legal fees, and against all judgments, fine and amounts paid in settlement and reasonably incurred in connection with legal, administrative or investigative proceedings any person who

&nbsp;&nbsp;&nbsp;&nbsp;a) in
 or was a party or is threatened to be made a party to any threatened, pending or completed proceedings, whether civil, criminal,
 administrative or investigative, by reason of the fact that the person is or was a director of the Company; or

b) is
 or was, at the request of the Company, serving as a director of, or in any other capacity is or was acting for, another body corporate
 or a partnership, joint venture, trust or other enterprise.

**Item 15. Recent Sales of Unregistered Securities.**

During the past three years, we have issued the following unregistered securities in transactions not involving a public offering:

In December 2025, we issued an aggregate of 4,280,340 shares of our Class A Common Stock upon the automatic conversion of four amended promissory notes at a fixed conversion price of $0.30 per share. These issuances occurred following the execution of separate Assignment and Amendment of Promissory Note agreements for each of the Company's four outstanding promissory notes. Under these agreements, each original noteholder (i.e., Barry Wan, New Lite Ventures LLC, and Hemeihui E-Commerce Co., Ltd.) assigned its amended note to either Atlantic Equity Holdings Inc. or Empire Street Capital Inc., with our consent. Immediately upon each assignment, the applicable amended promissory note automatically converted into shares of Class A Common Stock, resulting in the issuance of (i) 1,893,796 shares to Atlantic Equity Holdings Inc. and (ii) 2,386,544 shares to Empire Street Capital Inc.

On November 25, 2025, our majority stockholder approved, by written consent, the issuance of all Conversion Shares in connection with these Assignment and Amendment of Promissory Note agreements.

No shares were issued at the time the original promissory notes were issued in December 2024 because those notes were unsecured, non-interest-bearing loan obligations and did not contain conversion features at issuance.

The foregoing issuances were made without registration under the Securities Act of 1933, as amended, in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D, as the transactions did not involve any general solicitation and the purchasers were accredited investors. No underwriters participated in, or received any commissions or discounts from, these issuances.

[**Table of Contents**](#V_0000001)

**Item 16. EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1 | [Articles of Incorporation](https://www.sec.gov/Archives/edgar/data/1672571/000149315224024714/ex3-1.htm) |
| 3.2 | [Bylaws](https://www.sec.gov/Archives/edgar/data/1672571/000167257116000001/achisonarticlesbylaw.htm) |
| 5.1 | [Opinion of Celine and Partners, PLLC](ex5-1.htm) |
| 10.1 | [Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., Barry Wan (assignor), and Empire Street Capital Inc. (assignee).](ex10-1.htm) |
| 10.2 | [Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., New Lite Ventures LLC (assignor), and Atlantic Equity Holdings Inc. (assignee).](ex10-2.htm) |
| 10.3 | [Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., Hemeihui E-Commerce Co., Ltd. (assignor), Antiaging Doctor Hangzhou Holding Ltd. (original maker), and Atlantic Equity Holdings Inc. (assignee).](ex10-3.htm) |
| 10.4 | [Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., Hemeihui E-Commerce Co., Ltd. (assignor), Dao Ling Doctor (Zhejiang) Health Management Limited (original maker), and Empire Street Capital Inc. (assignee).](ex10-4.htm) |
| 10.5 | [Unanimous Written Consent of the Stockholder, dated November 25, 2025.](ex10-5.htm) |
| 10.6 | [Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Barry Wan, in the principal amount of $428,789.50.](ex10-6.htm) |
| 10.7 | [Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and New Lite Ventures LLC, in the principal amount of $29,571.00.](ex10-7.htm) |
| 10.8 | [Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Hemeihui E-Commerce Co., Ltd., in the principal amount of $538,568.00 (Dao Ling Doctor Hangzhou).](ex10-8.htm) |
| 10.9 | [Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Hemeihui E-Commerce Co., Ltd., in the principal amount of $287,174.00 (Dao Ling Doctor Zhejiang).](ex10-9.htm) |
| 10.10 | [Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Tairan Baohe Insurance Sales Co., Ltd., in the principal amount of $383,598.00.](ex10-10.htm) |
| 23.1 | [Consent of J&S ASSOCIATE PLT](ex23-1.htm) |
| 23.2 | [Consent of Celine and Partners, PLLC (included in Exhibit 5.1)](ex5-1.htm) |
| 24.1 | [Power of Attorney (included on signature page)](#V_0000002) |
| 107\* | Filing Fee Table |

---

\*To be filed by amendment

[**Table of Contents**](#V_0000001)

**Item 17. Undertakings.**

The undersigned hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

(2) That,
 for the purpose of determining liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to
 be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
 be deemed to be the initial bona fide offering thereof.

(3) To
 remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
 termination of the offering.

(4) That,
 for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b)
 as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other
 than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as
 of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus
 that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
 statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior
 to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the
 registration statement or made in any such document immediately prior to such date of first use.

(5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

[**Table of Contents**](#V_0000001)

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Flushing, New York, on December 5, 2025.

---

| | |
|:---|:---|
| Antiaging Quantum Living Inc. | Antiaging Quantum Living Inc. |
| By: | */s/ Barry Wan* |
|  | Barry Wan |
|  | Chief Executive Officer (Principal Executive Officer) |

---

**POWER OF ATTORNEY AND SIGNATURES**

The undersigned, a majority of the officers and directors of the company hereby constitute and appoint Barry Wan with full power of substitution, our true and lawful attorney-in-fact and agent to take any actions to enable the company to comply with the Securities Act, and any rules, regulations and requirements of the SEC, in connection with this registration statement, including the power and authority to sign for us in our names in the capacities indicated below any and all amendments to this registration statement and any other registration statement filed pursuant to the provisions of Rule 462 under the Securities Act.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Barry Wan* | Chief Executive Officer | December 5, 2025 |
| Barry Wan | (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) |  |

---

## Exhibit 5.1

**Exhibit 5.1**

**CELINE & PARTNERS, PLLC**

COUNSELLORS AT LAW

1185 6th Avenue, Suite 353

NEW YORK, NY 10036

—

TELEPHONE: (212) 612 - 1400

TELECOPIER: (718) 463 - 2555

December 5, 2025

Antiaging Quantum Living Inc.<br> 135-27 38th Avenue, #388

Flushing, New York 11354

Re: Registration Statement on Form S-1/A <br> Shares of Class A Common Stock

Ladies and Gentlemen:

We have acted as counsel to Antiaging Quantum Living Inc., a New York corporation (the "Company"), in connection with the preparation and filing by the Company of a Registration Statement on Form S-1/A (the "Registration Statement") under the Securities Act of 1933, as amended (the "Securities Act"), relating to the resale, from time to time, of an aggregate of 4,280,340 shares of the Company's Class A common stock, par value $0.00001 per share (the "Shares"), issued upon the automatic conversion of certain amended promissory notes pursuant to Assignment and Amendment of Promissory Note agreements (collectively, the "Note Amendments").

In rendering the opinions set forth herein, we have examined and relied upon originals or copies, certified or otherwise identified to our satisfaction, of the following documents: (i) the Company's Certificate of Incorporation and all amendments thereto; (ii) the Company's Bylaws; (iii) the Registration Statement; (iv) the Note Amendments; (v) resolutions of the Board of Directors and majority stockholder approving the Note Amendments and the issuance of the Shares; and (vi) such other documents, certificates, records and matters of law as we have deemed necessary or appropriate.

In our examination, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to original documents of all documents submitted to us as copies.

Based upon the foregoing, and subject to the qualifications, assumptions and limitations set forth herein, we are of the opinion that: (i) the Shares have been duly authorized by all necessary corporate action of the Company; and (ii) the Shares are validly issued, fully paid and non-assessable.

The opinions expressed herein are limited to the laws of the State of New York and the federal laws of the United States of America. We express no opinion with respect to the laws of any other jurisdiction.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to our firm under the caption "Legal Matters" in the Registration Statement. In giving this consent, we do not admit that we are "experts" within the meaning of Section 11 of the Securities Act or that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Securities and Exchange Commission.

Very truly yours,

CELINE & PARTNERS, PLLC

---

| | |
|:---|:---|
| By: | */s/ Cassi Olson* |

---

Cassi Olson, Esq.

Celine & Partners, PLLC

1185 Avenue of the Americas, STE. 353

New York, NY 10036

## Exhibit 10.1

**Exhibit 10.1**

![](ex10-1_001.jpg)

![](ex10-1_002.jpg)

![](ex10-1_003.jpg)

![](ex10-1_004.jpg)

## Exhibit 10.2

**Exhibit 10.2**

![](ex10-2_001.jpg)

![](ex10-2_002.jpg)

![](ex10-2_003.jpg)

![](ex10-2_004.jpg)

## Exhibit 10.3

**Exhibit 10.3**

![](ex10-3_001.jpg)

![](ex10-3_002.jpg)

![](ex10-3_003.jpg)

![](ex10-3_004.jpg)

## Exhibit 10.4

**Exhibit 10.4**

![](ex10-4_001.jpg)

![](ex10-4_002.jpg)

![](ex10-4_003.jpg)

![](ex10-4_004.jpg)

## Exhibit 10.5

**Exhibit 10.5**

![](ex10-5_001.jpg)

![](ex10-5_002.jpg)

## Exhibit 10.6

**Exhibit 10.6**

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE **"SECURITIES ACT").** THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

**PROMISSORY NOTE**

---

| | |
|:---|:---|
| Principal Amount: $428,789.50 | Dated as of December 31, 2024 |

---

Antiaging Quantum Living Inc, a New York corporation (the **"Maker"),** promises to pay to the order of Barry Wan, (the **"Payee")** the principal sum of Four Hundred Twenty-Eight Thousand, Seven Hundred Eighty-Nine Dollars and Fifty Cents Dollars ($428,789.50) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Promissory Note (this **"Note")** shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

1. **Principal.** The principal balance of this Note shall be on December 31, 2029. The principal
 balance may be prepaid at any time.

2. **Interest.** No interest shall accrue on the unpaid principal balance of this Note.

3. **Application of Payments.** All payments shall be applied first to payment in full of any costs incurred
 in the collection of any sum due under this Note, including (without limitation) reasonable
 attorney's fees, then to the payment in full of any late charges and finally to the
 reduction of the unpaid principal balance of this Note.

4. **Events of Default.** The following shall constitute an event of default **("Event of Default"):** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Failure
 to Make Required Payments. Failure by Maker to pay the principal of this Note within five
 (5) business days following the date when due.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Voluntary Liquidation, Etc.** The commencement by Maker of a proceeding relating to its bankruptcy,
 insolvency, reorganization, rehabilitation or other similar action, or the consent by it
 to the appointment of, or taking possession by, a receiver, liquidator, assignee, trustee,
 custodian, sequestrator (or other similar official) for Maker or for any substantial part
 of its property, or the making by it of any assignment for the benefit of creditors,
 or the failure of Maker generally to pay its debts as such debts become due, or the taking
 of corporate action by Maker in furtherance of any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **Involuntary Bankruptcy, Etc.** The entry of a decree or order for relief by a court having jurisdiction
 in the premises in respect of Maker in an involuntary case under any applicable bankruptcy,
 insolvency or similar law, for the appointing of a receiver, liquidator, assignee, custodian,
 trustee, sequestrator (or similar official) for Maker or for any substantial part of its
 property, or ordering the winding-up or liquidation of the affairs of Maker, and the continuance
 of any such decree or order unstayed and in effect for a period of 60 consecutive days.

5. **Remedies.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Upon
 the occurrence of an Event of Default specified in Section 5(a) hereof, the Payee may, by
 written notice to Maker, declare this Note to be due immediately and payable, whereupon the
 unpaid principal amount of this Note, and all other amounts payable hereunder, shall become
 immediately due and payable without presentment, demand, protest or other notice of any kind,
 all of which are hereby expressly waived, anything contained herein or in the documents evidencing
 the same to the contrary notwithstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Upon
 the occurrence of an Event of Default specified in Sections 5(b), the unpaid principal balance
 of this Note, and all other sums payable with regard to this Note, shall automatically and
 immediately become due and payable, in all cases without any action on the part of the Payee.

6. **Waivers.** Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment
 for payment, demand, notice of dishonor, protest, and notice of protest with regard to the
 Note, all errors, defects and imperfections in any proceedings instituted by the Payee under
 the terms of this Note, and all benefits that might accrue to Maker by virtue of any present
 or future laws exempting any property, real or personal, or any part of the proceeds arising
 from any sale of any such property, from attachment, levy or sale under execution, or providing
 for any stay of execution, exemption from civil process, or extension of time for payment;
 and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained
 by vi1iue hereof, on any writ of execution issued hereon, may be sold upon any such writ
 in whole or in pa1i in any order desired by the Payee.

7. **Unconditional Liability.** Maker hereby waives all notices in connection with the delivery, acceptance,
 performance, default, or enforcement of the payment of this Note, and agrees that its liability
 shall be unconditional, without regard to the liability of any other party, and shall not
 be affected in any manner by any indulgence, extension of time, renewal, waiver or modification
 granted or consented to by the Payee, and consents to any and all extensions of time, renewals,
 waivers, or modifications that may be granted by the Payee with respect to the payment or
 other provisions of this Note, and agrees that additional makers, endorsers, guarantors,
 or sureties may become parties hereto without notice to Maker or affecting Maker's
 liability hereunder.

8. **Notices.** Any notice called for hereunder shall be deemed properly given if (i) sent by certified
 mail, return receipt requested, (ii) personally delivered, (iii) dispatched by any form of
 private or governmental express mail or delivery service providing receipted delivery or
 (iv) sent by facsimile or (v) to the following addresses or to such other address as either
 pa1iy may designate by notice in accordance with this Section:

If to Maker:

135-27 38th Ave #388

Flushing, NY 11354

Attn: Barry Wan

If to Payee:

135-27 38th Ave #388

Flushing, NY 11354

Attn: Barry Wan

Notice shall be deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii) the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service.

9. **Construction.** THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF
 NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

10. **Jurisdiction.** The courts of the State of New York have exclusive jurisdiction to settle any dispute arising
 out of or in connection with this agreement (including a dispute relating to any non-contractual
 obligations arising out of or in connection with this agreement) and the parties submit to
 the exclusive jurisdiction of the courts of New York.

11. **Severability.** Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction
 shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability
 without invalidating the remaining provisions hereof, and any such prohibition or unenforceability
 in any jurisdiction shall not invalidate or render unenforceable such provision in any other
 jurisdiction.

12. **Amendment; Waiver.** Any amendment hereto or waiver of any provision hereof may be made with, and
 only with, the written consent of the Maker and the Payee.

13. **Assignment.** No assignment or transfer of this Note or any rights or obligations hereunder may be
 made by any party hereto (by operation of law or otherwise) without the prior written consent
 of the other party hereto and any attempted assignment without the required consent shall
 be void.

14. **Further Assurance.** The Maker shall, at its own cost and expense, execute and do (or procure to
 be executed and done by any other necessary party) all such deeds, documents, acts and things
 as the Payee may from time to time require as may be necessary to give full effect to this
 Note.

*[The rest of this page is intentionally left blank]*

 

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.

---

| | |
|:---|:---|
| ANTTAGING QUANTUM LIVING INC | ANTTAGING QUANTUM LIVING INC |
| By: | /s/ Barry Wan |
| Name: | Barry Wan |
| Title: | Chairman and CEO |

---

---

| | |
|:---|:---|
| Accepted and Agreed: | Accepted and Agreed: |
| BARRY WAN | BARRY WAN |
| By: | /s/ Barry Wan |

---

*[Signature Page to Promissory Note}*

## Exhibit 10.7

**Exhibit 10.7**

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE **"SECURITIES ACT").** THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

**PROMISSORY NOTE**

---

| | |
|:---|:---|
| Principal Amount: $29,571.00 | Dated as of December 31, 2024 |

---

Antiaging Quantum Living Inc., a New York corporation (the **"Maker"),** promises to pay to the order of New Lite Ventures LLC, (the **"Payee")** the principal sum of twenty-nine thousand, five hundred seventy-one dollars ($29,571.00) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Promissory Note (this **"Note")** shall be made by check or wire transfer of immediately available funds or as othe1wise dete1mined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

1. **Principal.** The principal balance of this Note shall be on December 31, 2029. The principal balance
 may be prepaid at any time.

2. **Interest.** No interest shall accrue on the unpaid principal balance of this Note.

3. **Application of Payments.** All payments shall be applied first to payment in full of any costs incurred
 in the collection of any sum due under this Note, including (without limitation) reasonable
 attorney's fees, then to the payment in full of any late charges and finally to the
 reduction of the unpaid principal balance of this Note.

4. Events
 of Default. The following shall constitute an event of default ("Event of Default"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Failure to Make Required Payments.** Failure by Maker to pay the principal of this Note within
 five (5) business days following the date when due.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Voluntary Liquidation, Etc.** The commencement by Maker of a proceeding relating to its bankruptcy,
 insolvency, reorganization, rehabilitation or other similar action, or the consent by it
 to the appointment of, or taking possession by, a receiver, liquidator, assignee, trustee,
 custodian, sequestrator (or other similar official) for Maker or for any substantial part
 of its property, or the making by it of any assignment for the benefit of creditors, or the
 failure of Maker generally to pay its debts as such debts become due, or the taking of corporate
 action by Maker in furtherance of any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **Involuntary Bankruptcy, Etc.** The entry of a decree or order for relief by a court having jurisdiction
 in the premises in respect of Maker in an involuntary case under any applicable bankruptcy,
 insolvency or similar law, for the appointing of a receiver, liquidator, assignee, custodian,
 trustee, sequestrator (or similar official) for Maker or for any substantial part of its
 property, or ordering the winding-up or liquidation of the affairs of Maker, and the continuance
 of any such decree or order unstayed and in effect for a period of 60 consecutive days.

5. **Remedies.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Upon
 the occurrence of an Event of Default specified in Section 5(a) hereof, the Payee
 may, by written notice to Maker, declare this Note to be due immediately and payable, whereupon
 the unpaid principal amount of this Note, and all other amounts payable hereunder, shall
 become immediately due and payable without presentment, demand, protest or other notice of
 any kind, all of which are hereby expressly waived, anything contained herein or in the documents
 evidencing the same to the contrary notwithstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Upon
 the occurrence of an Event of Default specified in Sections 5(6), the unpaid principal balance
 of this Note, and all other sums payable with regard to this Note, shall automatically and
 immediately become due and payable, in all cases without any action on the part of the Payee.

6. **Waivers.** Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment
 for payment, demand, notice of dishonor, protest, and notice of protest with regard to the
 Note, all errors, defects and imperfections in any proceedings instituted by the Payee under
 the terms of this Note, and all benefits that might accrue to Maker by virtue of any
 present or future laws exempting any property, real or personal, or any part of the
 proceeds arising from any sale of any such prope1ty, from attachment, levy or sale under
 execution, or providing for any stay of execution, exemption from civil process, or extension
 of time for payment; and Maker agrees that any real estate that may be levied upon pursuant
 to a judgment obtained by virtue hereof, on any writ of execution issued hereon, may be sold
 upon any such writ in whole or in part in any order desired by the Payee.

7. **Unconditional Liability.** Maker hereby waives all notices in connection with the delive1y, acceptance,
 performance, default, or enforcement of the payment of this Note, and agrees that its liability
 shall be unconditional, without regard to the liability of any other party, and shall not
 be affected in any manner by any indulgence, extension of time, renewal, waiver or modification
 granted or consented to by the Payee, and consents to any and all extensions of time, renewals,
 waivers, or modifications that may be granted by the Payee with respect to the payment or
 other provisions of this Note, and agrees that additional makers, endorsers, guarantors,
 or sureties may become parties hereto without notice to Maker or affecting Maker's
 liability hereunder.

8. **Notices.** Any notice called for hereunder shall be deemed properly given if (i) sent by certified
 mail, return receipt requested, (ii) personally delivered, (iii) dispatched by any form of
 private or governmental express mail or delivery service providing receipted delivery or
 (iv) sent by facsimile or (v) to the following addresses or to such other address as either
 party may designate by notice in accordance with this Section:

If to Maker:

135-27 38th Ave #388

Flushing, NY 11354

Attn: Barry Wan

If to Payee:

135-27 38th Ave #388

Flushing, NY 11354

Attn: Bany Wan

Notice shall be deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii) the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service.

9. **Construction.** THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW
 YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

10. **Jurisdiction.** The courts of the State of New York have exclusive jurisdiction to settle any dispute arising
 out of or in connection with this agreement (including a dispute relating to any non-contractual
 obligations arising out of or in connection with this agreement) and the parties submit to
 the exclusive jurisdiction of the courts of New York.

11. **Severability.** Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction
 shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability
 without invalidating the remaining provisions hereof, and any such prohibition or
 unenforceability m any jurisdiction shall not invalidate or render unenforceable such provision
 in any other jurisdiction.

12. **Amendment; Waiver.** Any amendment hereto or waiver of any provision hereof may be made with, and
 only with, the written consent of the Maker and the Payee.

13. **Assignment.** No assignment or transfer of this Note or any rights or obligations hereunder may be
 made by any party hereto (by operation of law or otherwise) without the prior written consent
 of the other party hereto and any attempted assignment without the required consent shall
 be void.

14. **Further Assurance.** The Maker shall, at its own cost and expense, execute and do (or procure to
 be executed and done by any other necessary party) all such deeds, documents, acts and things
 as the Payee may from time to time require as may be necessa1y to give full effect to this
 Note.

*[The rest of this page is intentionally left blank]*

 

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.

---

| | |
|:---|:---|
| ANTIAGTNG QUANTUM LIVING INC | ANTIAGTNG QUANTUM LIVING INC |
| By: | /s/ Barry Wan |
| Name: | Barry Wan |
| Title: | Chairman and CEO |

---

Accepted and Agreed:

---

| | |
|:---|:---|
| NEW LITE VENTURES LLC | NEW LITE VENTURES LLC |
| By: | /s/ Barry Wan |
| Name: | Wan |
| Title: | Sole Member |

---

*[Signature Page to Promissory Note]*

## Exhibit 10.8

**Exhibit 10.8**

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE **"SECURITIES ACT").** THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF TI-IE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

**PROMISSORY NOTE**

---

| | |
|:---|:---|
| Principal Amount: $538,568.00 | Dated as of December 31, 2024 |

---

Antiaging Doctor Hangzhou Holding LTD, a China corporation (the **"Maker"),** promises to pay to the order of Hemeihui E-Commerce Co., Ltd. (the **"Payee")** the principal sum of Five hundred thirty-eight thousand, five hundred sixty-eight dollars ($538,568.00) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Promissory Note (this **"Note")** shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Principal.** The principal balance of this Note shall be on [December 31, 2029]. The principal balance may be prepaid at any time.

2. **Interest.** No interest shall accrue on the unpaid principal balance of this Note.

3. **Application of Payments.** All payments shall be applied first to payment in full of any costs incurred in the collection of any sum due under
 this Note, including (without limitation) reasonable attorney's fees, then to the payment in full of any late charges and finally
 to the reduction of the unpaid principal balance of this Note.

4. **Events of Default.** The following shall constitute an event of default **("Event of Default"):** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Failure to Make Required Payments.** Failure by Maker to pay the principal of this Note within five (5) business days following the date
 when due.

(b) Voluntary
 Liquidation, Etc. The commencement by Maker of a proceeding relating to its bankruptcy, insolvency,
 reorganization, rehabilitation or other similar action, or the consent by it to the appointment
 of, or taking possession by, a receiver, liquidator, assignee, trustee, custodian, sequestrator
 (or other similar official) for Maker or for any substantial part of its property, or the
 making by it of any assignment for the benefit of creditors, or the failure of Maker generally
 to pay its debts as such debts become due, or the taking of corporate action by Maker in
 furtherance of any of the foregoing.

(c) Involuntary
 Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Maker in
 an involuntary case under any applicable bankruptcy, insolvency or similar law, for the appointing of a receiver, liquidator, assignee,
 custodian, trustee, sequestrator (or similar official) for Maker or for any substantial part of its property, or ordering the winding-up
 or liquidation of the affairs of Maker, and the continuance of any such decree or order unstayed and in effect for a period of 60
 consecutive days.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.** **Remedies.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Upon
 the occurrence of an Event of Default specified in Section 5(a) hereof, the Payee may, by written notice to Maker, declare this Note
 to be due immediately and payable, whereupon the unpaid principal amount of this Note, and all other amounts payable hereunder, shall
 become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly
 waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.

(b) Upon
 the occurrence of an Event of Default specified in Sections 5(6), the unpaid principal balance of this Note, and all other sums payable
 with regard to this Note, shall automatically and immediately become due and payable, in all cases without any action on the part
 of the Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **Waivers.** Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor,
 protest, and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by the
 Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting
 any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or
 sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and
 Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of execution
 issued hereon, may be sold upon any such writ in whole or in part in any order desired by the Payee.

7. **Unconditional Liability.** Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement
 of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party,
 and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented
 to by the Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by the Payee
 with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties
 may become parties hereto without notice to Maker or affecting Maker's liability hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **Notices.** Any notice called for hereunder shall be deemed properly given if (i) sent by certified mail, return receipt requested, (ii)
 personally delivered, (iii) dispatched by any form of private or governmental express mail or delivery service providing receipted
 delivery or (iv) sent by facsimile or (v) to the following addresses or to such other address as either party may designate by notice
 in accordance with this Section:

If to Maker:

Room 1002, Floor 10, Building I

Xiaoshankechuang Center, Beigan Street

Xiaoshan District, Hangzhou City, Zhejiang Province

Attn: Bany Wan

If to Payee:

[58 Fumin Zhilu, Hengsha Township

Chongming District, Shanghai]

Attn: Tingting Jiang

Notice shall be deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii) the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. **Construction.** THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW
 PROVISIONS THEREOF.

10. **Jurisdiction.** The courts of the State of New York have exclusive jurisdiction to settle any dispute arising out of or in connection with this
 agreement (including a dispute relating to any non-contractual obligations arising out of or in connection with this agreement) and
 the parties submit to the exclusive jurisdiction of the courts of New York.

11. **Severability.** Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
 be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any
 such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other
 jurisdiction.

12. **Amendment; Waiver.** Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker
 and the Payee.

13. **Assignment.** No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law
 or otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent
 shall be void.

14. **Further Assurance.** The Maker shall, at its own cost and expense, execute and do (or procure to be executed and done by any other necessary
 party) all such deeds, documents, acts and things as the Payee may from time to time require as may be necessary to give full effect
 to this Note.

*[The rest of this page is intentionally left blank}*

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.

---

| | |
|:---|:---|
| Antiaging Doctor Hangzhou Holding LTD | Antiaging Doctor Hangzhou Holding LTD |
| By: | /s/ Yipeng Qi |
| Name: | Yipeng Qi |
| Title: | Duly Authorized Signatory |

---

---

| | |
|:---|:---|
| Accepted and Agreed: | Accepted and Agreed: |
| Hemeihui E-Commerce Co., Ltd. | Hemeihui E-Commerce Co., Ltd. |
| By: | /s/ Tingling Jiang |
| Name: | Tingling Jiang |
| Title: | Duly Authorized Signatory |

---

*[Signature Page to Promissory Note]*

## Exhibit 10.9

**Exhibit 10.9**

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE **"SECURITIES ACT").** THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

**PROMISSORY NOTE**

---

| | |
|:---|:---|
| Principal Amount: $287,174.00 | Dated as of December 31, 2024 |

---

Dao Ling Doctor (Zhejiang) Health Management Limited, a China corporation (the **"Maker"),** promises to pay to the order of Hemeihui E-Commerce Co., Ltd. (the **"Payee")** the principal sum of Two hundred eighty-seven thousand, one hundred seventy-four dollars ($287,174.00) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Promissory Note (this **"Note")** shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Principal.** The principal balance of this Note shall be on [December 31, 2029]. The principal balance
 may be prepaid at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **Interest.** No interest shall accrue on the unpaid principal balance of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Application of Payments.** All payments shall be applied first to payment in full of any costs incurred
 in the collection of any sum due under this Note, including (without limitation) reasonable
 attorney's fees, then to the payment in full of any late charges and finally to the reduction
 of the unpaid principal balance of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **Events of Default.** The following shall constitute an event of default **("Event of Default"):** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Failure
 to Make Required Payments. Failure by Maker to pay the principal of this Note within five
 (5) business days following the date when due.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Voluntary
 Liquidation, Etc. The commencement by Maker of a proceeding relating to its bankruptcy, insolvency,
 reorganization, rehabilitation or other similar action, or the consent by it lo the appointment
 of, or taking possession by, a receiver, liquidator, assignee, trustee, custodian, sequestralor
 (or other similar official) for Maker or for any substantial pait of its prope11y, or the
 making by it of any assignment for the benefit of creditors, or the failure of Maker generally
 to pay its debts as such debts become due, or the taking of corporate action by Maker in
 futtherance of any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Involuntary
 Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction
 in the premises in respect of Maker in an involuntary case under any applicable bankruptcy,
 insolvency or similar law, for the appointing of a receiver, liquidator, assignee, custodian,
 trustee, sequestrator (or similar official) for Maker or for any substantial part of its
 property, or ordering the winding-up or liquidation of the affairs of Maker, and the continuance
 of any such decree or order unstayed and in effect for a period of 60 consecutive days.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **Remedies.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Upon
 the occurrence of an Event of Default specified in Section 5(a) hereof, the Payee may, by
 written notice to Maker, declare this Note to be due immediately and payable, whereupon the
 unpaid principal amount of this Note, and all other amounts payable hereunder, shall become
 immediately due and payable without presentment, demand, protest or other notice of any kind,
 all of which are hereby expressly waived, anything contained herein or in the documents evidencing
 the same to the contrary notwithstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Upon
 the occurrence of an Event of Default specified in Sections S(b), the unpaid principal balance
 of this Note, and all other sums payable with regard to this Note, shall automatically and
 immediately become due and payable, in all cases without any action on the part of the Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **Waivers.** Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment
 for payment, demand, notice of dishonor, protest, and notice of protest with regard to the
 Note, all errors, defects and imperfections in any proceedings instituted by the Payee under
 the terms of this Note, and all benefits that might accrue to Maker by virtue of any present
 or future laws exempting any propetty, real or personal, or any part of the proceeds arising
 from any sale of any such propetty, from attachment, levy or sale under execution, or providing
 for any stay of execution, exemption from civil process, or extension of time for payment;
 and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained
 by virtue hereof, on any writ of execution issued hereon, may be sold upon any such writ
 in whole or in part in any order desired by the Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Unconditional
 Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance,
 default, or enforcement of the payment of this Note, and agrees that its liability shall
 be unconditional, without regard to the liability of any other party, and shall not be affected
 in any manner by any indulgence, extension of time, renewal, waiver or modification granted
 or consented to by the Payee, and consents to any and all extensions of time, renewals, waivers,
 or modifications that may be granted by the Payee with respect to the payment or other provisions
 of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become
 parties hereto without notice to Maker or affecting Maker's liability hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **Notices.** Any notice called for hereunder shall be deemed properly given if (i) sent by certified
 mail, return receipt requested, (ii) personally delivered, (iii) dispatched by any form of
 private or governmental express mail or delivery service providing receipted delivery or
 (iv) sent by facsimile or (v) to the following addresses or to such other address as either
 party may designate by notice in accordance with this Section:

If to Maker:

I002-2, Floor I0, Building I,

Xiaoshankechuang Center

Beigan Street,

Xiaoshan District

Hangzhou City, Zhejiang Province

Attn: Barry Wan

If to Payee:

[58 Fumin Zhilu, Hengsha Township

Chongming District, Shanghai]

Attn: Tingting Jiang

Notice shall be deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii) the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. **Construction.** THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW
 YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. **Jurisdiction.** The courts of the State of New York have exclusive jurisdiction to settle any dispute
 arising out of or in connection with this agreement (including a dispute relating to any
 non-contractual obligations arising out of or in connection with this agreement) and the
 parties submit to the exclusive jurisdiction of the courts of New York.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. **Severability.** Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction
 shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability
 without invalidating the remaining provisions hereof, and any such prohibition or unenforceability
 in any jurisdiction shall not invalidate or render unenforceable such provision in any other
 jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. **Amendment; Waiver.** Any amendment hereto or waiver of any provision hereof may be made with, and
 only with, the written consent of the Maker and the Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. **Assignment.** No assignment or transfer of this Note or any rights or obligations hereunder may be made
 by any party hereto (by operation of law or otherwise) without the prior written consent
 of the other party hereto and any attempted assignment without the required consent shall
 be void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. **Further Assurance.** The Maker shall, at its own cost and expense, execute and do (or procure to
 be executed and done by any other necessary party) all such deeds, documents, acts and things
 as the Payee may from time to time require as may be necessary to give full effect to this
 Note.

*[The rest of this page is intentionally left blank]*

 

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.

---

| | |
|:---|:---|
| Dao Ling Doctor (Zhejiang) Health Management Limited | Dao Ling Doctor (Zhejiang) Health Management Limited |
| &nbsp;&nbsp;&nbsp;&nbsp;By: | /s/ Yipeng Qi |
| Name: | Yipeng Qi |
| Title: | Duly Authorized Signatory |

---

---

| | |
|:---|:---|
| Accepted and Agreed: | Accepted and Agreed: |
| Hemeihui E-Commerce Co., Ltd. By: | Hemeihui E-Commerce Co., Ltd. By: |
| By: | /s/ Tingling Jiang |
| Name: | Tingling Jiang |
| Title: | Duly Authorized Signatory |

---

 

*[Signature Page to Promissory Note]*

## Exhibit 10.10

**Exhibit 10.10**

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITJES ACT OF 1933, AS AMENDED (THE **"SECURITIES ACT").** THIS NOTE HAS BEEN ACQUlRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

**PROMISSORY NOTE**

---

| | |
|:---|:---|
| Principal Amount: $383,598.00 | Dated as of December 31, 2024 |

---

Antiaging Doctor Hangzhou Holding LTD, a China corporation (the **"Maker"),** promises to pay to the order of Tairan Baohe Insurance Sales Co., Ltd. (the **"Payee")** the principal sum of three hundred eighty-three thousand, five hundred ninety-eight dollars ($383,598.00) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Promissory Note (this **"Note")** shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Principal.** The principal balance of this Note shall be on [December 31, 2029]. The principal balance
 may be prepaid at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **Interest.** No interest shall accrue on the unpaid principal balance of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Application of Payments.** All payments shall be applied first to payment in full of any costs incurred
 in the collection of any sum due under this Note, including (without limitation) reasonable
 attorney's fees, then to the payment in full of any late charges and finally to the
 reduction of the unpaid principal balance of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **Events of Default.** The following shall constitute an event of default **("Event of Default"):** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Failure
 to Make Required Payments. Failure by Maker to pay the principal of this Note within five
 (5) business days following the date when due.

(b) **Voluntary Liquidation, Etc.** The commencement by Maker of a proceeding relating to its bankruptcy,
 insolvency, reorganization, rehabilitation or other similar action, or the consent by it
 to the appointment of, or taking possession by, a receiver, liquidator, assignee, trustee,
 custodian, sequestrator (or other similar official) for Maker or for any substantial part
 of its property, or the making by it of any assignment for the benefit of creditors, or the
 failure of Maker generally to pay its debts as such debts become due, or the taking of corporate
 action by Maker in furtherance of any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Involuntary
 Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction
 in the premises in respect of Maker in an involuntary case under any applicable bankruptcy,
 insolvency or similar law, for the appointing of a receiver, liquidator, assignee, custodian,
 trustee, sequestrator (or similar official) for Maker or for any substantial part of its
 property, or ordering the winding-up or liquidation of the affairs of Maker, and the continuance
 of any such decree or order unstayed and in effect for a period of 60 consecutive days.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **Remedies.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Upon
 the occurrence of an Event of Default specified in Section S(a) hereof, the Payee may, by
 written notice to Maker, declare this Note to be due immediately and payable, whereupon the
 unpaid principal amount of this Note, and all other amounts payable hereunder, shall become
 immediately due and payable without presentment, demand, protest or other notice of any kind,
 all of which are hereby expressly waived, anything contained herein or in the documents evidencing
 the same to the contrary notwithstanding.

(b) Upon
 the occurrence of an Event of Default specified in Sections S(b), the unpaid principal balance
 of this Note, and all other sums payable with regard to this Note, shall automatically and
 immediately become due and payable, in all cases without any action on the part of the Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **Waivers.** Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment
 for payment, demand, notice of dishonor, protest, and notice of protest with regard to the
 Note, all errors, defects and imperfections in any proceedings instituted by the Payee under
 the terms of this Note, and all benefits that might accrue to Maker by virtue of any present
 or future laws exempting any property, real or personal, or any part of the proceeds arising
 from any sale of any such property, from attachment, levy or sale under execution, or providing
 for any stay of execution, exemption from civil process, or extension of time for payment;
 and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained
 by virtue hereof, on any writ of execution issued hereon, may be sold upon any such writ
 in whole or in part in any order desired by the Payee.

7. Unconditional
 Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance,
 default, or enforcement of the payment of this Note, and agrees that its liability shall
 be unconditional, without regard to the liability of any other patty, and shall not be affected
 in any manner by any indulgence, extension of time, renewal, waiver or modification granted
 or consented to by the Payee, and consents to any and all extensions of time, renewals, waivers,
 or modifications that may be granted by the Payee with respect to the payment or other provisions
 of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become
 parties hereto without notice to Maker or affecting Maker's liability hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **Notices.** Any notice called for hereunder shall be deemed properly given if (i) sent by certified mail,
 return receipt requested, (ii) personally delivered, (iii) dispatched by any form of private
 or governmental express mail or delivery service providing receipted delivery or (iv) sent
 by facsimile or (v)
to the following addresses or to such other address as either party may designate by notice in accordance with this Section:

If to Maker:

Room I 002, Floor 10, Building 1

Xiaoshankechuang Center, Beigan Street

Xiaoshan District, Hangzhou City, Zhejiang Province

Attn: Barry Wan

lf to Payee:

[Room 1710-1711, Building 2

Zhongxing City, Haiyao Business Center

Northeast Side ofDongyi Ring Road

Yaohai District, Hefei City, Anhui Province]

Attn: Qi Chen

Notice shall be deemed given on the earlier of (i) actual receipt by the receiving patty, (ii) the date shown on a facsimile transmission confirmation, (iii) the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service.

---

| | |
|:---|:---|
| 9. | **Construction.** THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF. |
| I0. | **Jurisdiction.** The courts of the State of New York have exclusive jurisdiction to settle any dispute arising out of or in connection with this agreement (including a dispute relating to any non-contractual obligations arising out of or in connection with this agreement) and the parties submit to the exclusive jurisdiction of the courts of New York. |
| 11. | **Severability.** Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. |
| 12. | **Amendment; Waiver.** Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker and the Payee. |
| 13. | **Assignment.** No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent shall be void. |
| 14. | **Further Assurance**. The Maker shall, at its own cost and expense, execute and do (or procure to be executed and done by any other necessary party) all such deeds, documents, acts and things as the Payee may from time to time require as may be necessary to give full effect to this Note. |

---

*[The rest of this page is intentionally left blank]*

 

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.

---

| | |
|:---|:---|
| Antiaging Doctor Hangzhou Holding LTD | Antiaging Doctor Hangzhou Holding LTD |
| By: | /s/ Yipeng Qi |
| Name: | Yipeng Qi |
| Title: | Duly Authorized Signatory |

---

---

| | |
|:---|:---|
| Accepted and Agreed: | Accepted and Agreed: |
| Tairan Baohe Insurance Sales Co., Ltd. | Tairan Baohe Insurance Sales Co., Ltd. |
| By: | /s/ Qi Chen |
| Name: | Qi Chen |
| Title: | Duly Authorized Signatory |

---

*[Signature Page to Promissory Note}*

## Exhibit 23.1

**Exhibit 23.1**

---

| | | |
|:---|:---|:---|
| ![](ex23-1_001.jpg) | **J&S ASSOCIATE PLT**<br>202206000037 (LLP0033395-LCA) & AF002380<br> (Registered with PCAOB and MIA)<br> B-11-14, Megan Avenue II<br> 12,Jalan Yap Kwan Seng, 50450, Kuala Lumpur, Malaysia<br>| Tel: +603-4813 9469<br> Email : info@jns-associate.com<br> Website : jns-associate.com |

---

------

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference on Form S-1 (333-211051) of Antiaging Quantum Living Inc., of our report dated July 2, 2025, relating to the consolidated financial statements appearing in the Annual Report on this Form 10-K of Antiaging Quantum Living Inc. for the year ended March 31, 2025.

We also consent to the reference to our Firm under the caption "Experts" appearing in such Form S-1 (333-211051).

---

| |
|:---|
| /s/ J&S Associate PLT |
| Kuala Lumpur, Malaysia |
| December 5, 2025 |

---